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understood, but previous studies have found that this process involves the methyl-CpG binding
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and chromatin states. Genetic studies also linked MeCP2 and MBD1 to neurodevelopmental
disorders in humans and mice. However, a role for MBD2 in the brain has not been described. In
this work, we characterized the phenotypes of mice lacking MBD2. We found that, unlike MeCP2
and MBD1, Mbd2 null mice behave similarly to wildtype littermates, with the exception of mildly
altered nesting and locomotor activity and reduced body weight. To investigate the underlying
cause of different functional requirements for the MBDs, we generated knockin mice in which
endogenous MBD2 and MBD1 are biotin-tagged. We systematically compared the spatiotemporal
expression patterns of the MBDs and found that MeCP2, MBD1 and MBD3 are primarily
expressed in the brain. In contrast, MBD2 is widely expressed throughout the body at young and
adult ages. In addition, the expression of MBD2 is upregulated in adult spleen and small intestine
compared to younger ages, while MBD1 and MBD3 are only enriched at early ages in the brain.
We also determined that MBD2 interacts with the NuRD complex ubiquitously across tissues. We
conclude that MBD2 is likely dispensable for brain function and instead may mediate NuRDrelated
functions primarily in peripheral tissues. Our study provides novel genetic tools and
reveals new directions to investigate MBD2 functions in vivo.
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ABSTRACT 
INSIGHTS INTO MBD2 FUNCTION REVEALED BY A NOVEL 
GENETIC TAGGING APPROACH 
Kathleen H. Wood 
Zhaolan Zhou, Ph.D. 
 
 Methylation of cytosine is an epigenetic mark essential for many cellular and 
developmental processes. How methylation is interpreted into transcriptional regulation is not fully 
understood, but previous studies have found that this process involves the methyl-CpG binding 
domain (MBD) family of proteins. Three MBD proteins, MeCP2, MBD1 and MBD2, specifically 
bind methylated cytosines and recruit different co-repressor complexes to regulate transcription 
and chromatin states. Genetic studies also linked MeCP2 and MBD1 to neurodevelopmental 
disorders in humans and mice. However, a role for MBD2 in the brain has not been described. In 
this work, we characterized the phenotypes of mice lacking MBD2. We found that, unlike MeCP2 
and MBD1, Mbd2 null mice behave similarly to wildtype littermates, with the exception of mildly 
altered nesting and locomotor activity and reduced body weight. To investigate the underlying 
cause of different functional requirements for the MBDs, we generated knockin mice in which 
endogenous MBD2 and MBD1 are biotin-tagged. We systematically compared the spatiotemporal 
expression patterns of the MBDs and found that MeCP2, MBD1 and MBD3 are primarily 
expressed in the brain. In contrast, MBD2 is widely expressed throughout the body at young and 
adult ages. In addition, the expression of MBD2 is upregulated in adult spleen and small intestine 
compared to younger ages, while MBD1 and MBD3 are only enriched at early ages in the brain. 
We also determined that MBD2 interacts with the NuRD complex ubiquitously across tissues. We 
conclude that MBD2 is likely dispensable for brain function and instead may mediate NuRD-
related functions primarily in peripheral tissues. Our study provides novel genetic tools and 
reveals new directions to investigate MBD2 functions in vivo.  
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CHAPTER 1: Introduction 
Adapted from: Wood KH and Zhou Z. Emerging Molecular and Biological Functions of MBD2, a 
Reader of DNA Methylation. Frontiers in Genetics. Submitted. 
 
DNA METHYLATION AND ITS READERS 
 
Establishment of DNA methylation and oxidized forms 
 DNA methylation at the 5’ position of cytosine (mC) is a chemical modification that is 
essential for mammalian viability and development (Smith and Meissner, 2013; Suzuki and Bird, 
2008). DNA methylation at CpG dinucleotides (mCG) has historically been associated with gene 
repression; however, recent advances have revealed a complex role for DNA methylation in 
regards to its dynamic turnover, cell type specific distribution patterns and effect on transcriptional 
regulation (Suzuki and Bird, 2008). DNA is methylated by the de novo methyltransferases 
DNMT3A and DNMT3B (Okano et al., 1999), in association with DNMT3L (Bourc’his et al., 2001), 
and the mark is maintained through cell division by the maintenance methyltransferase DNMT1 
(Yoder and Bestor, 1998). Passive demethylation occurs in the absence of DNMT activity as cells 
divide without maintenance methylation (Chen et al., 2003). Active demethylation also occurs 
through the conversion of mC to hydroxymethylcytosine (hmC) by the ten-eleven translocation 
(TET) family of proteins (Tahiliani et al., 2009). hmC can be further oxidized by the TET proteins 
to 5-formylcytosine (5fC) and 5-carboxylcytosine (5caC) (Ito et al., 2011), which is then modified 
by thymine-DNA glycosylase (TDG) and can be replaced with an unmodified cytosine through 
base excision repair (BER) mechanisms (He et al., 2011). Alternatively, hmC can lead to passive 
demethylation even in cells expressing the maintenance methyltransferase DNMT1, as it is a 
poor substrate for this enzyme (Hashimoto et al., 2012a).These processes together complete the 
cycle of cytosine modification (Figure 1.1).  
 Methylation and its oxidized forms are also found outside of the CpG context (mCH) in 
many cell types (Lister et al., 2009; Schultz et al., 2015). While mCG is the most abundant 
 
 2 
modification, both mCH and hmC are also detected across tissues and are highly enriched in 
embryonic stem cells (ESCs) and the brain (Lister et al., 2009, 2013; Schultz et al., 2015). The 
distribution of these modifications is developmentally dynamic and cell-type specific, but the 
mechanisms that direct the precise establishment of these patterns have yet to be fully 
determined (Pastor et al., 2013; Schübeler, 2015). It is critical to gain further understanding of the 
mechanisms of DNA methylation because these findings will in turn aid in our elucidation of other 
biological processes, including the differentiation of pluripotent cells, neuronal development and 
function, and tumorigenesis, amongst many others. 
 
DNA methylation and transcriptional regulation 
It is well established that methylation affects transcriptional regulation differently 
depending on the genomic context. Most CpG sites in the mammalian genome are methylated, 
with the exception of CpG-dense, hypomethylated domains at putative regulatory elements or 
promoter regions called CpG islands (CGI) (Deaton and Bird, 2011). A subset of CGIs are highly 
methylated and induce transcriptional silencing of the associated gene with cell-type specificity 
(Deaton and Bird, 2011; Illingworth et al., 2008). Highly methylated CGIs also correspond to 
regions with long-term or constitutive silencing, such as imprinted genes (Li et al., 1993), the 
inactive X chromosome (Csankovszki et al., 2001), and endogenous retroviruses (Walsh et al., 
1998). In contrast, increased mCG and particularly mCH density across the gene body is 
associated with transcriptional activation (Maunakea et al., 2010; Mo et al., 2015; Yang et al., 
2014b). hmC is also associated with active regulatory and transcribed regions and is dynamically 
regulated throughout development (Lister et al., 2013; Pastor et al., 2011; Stroud et al., 2011).  
DNA methylation is intimately linked to other epigenetic factors and together these 
mechanisms comprise the chromatin state and direct gene expression programs (reviewed in 
(Chen and Dent, 2014). However, it is not clear how or in what order histone modifications and 
DNA methylation are established and how they influence each other (Cedar and Bergman, 2009; 
Schübeler, 2015; Spruijt and Vermeulen, 2014; Suzuki and Bird, 2008). Different histone marks 
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correlate with different regions of chromatin, such as promoters, enhancers and coding regions 
(Kim and Shiekhattar, 2015). Different histone modifications also direct the binding of many 
factors to DNA and can affect DNA methylation deposition by the differential recruitment of 
DNMTs (Baubec et al., 2015; Eberl et al., 2013; Noh et al., 2015). Conversely, DNA methylation, 
or the absence of methylation at CGIs, can direct the establishment of different histone marks 
(Thomson et al., 2010). 
DNA methylation can also directly determine how and where protein factors bind to DNA. 
Transcription factors can be repelled by methylation at promoters (Blattler and Farnham, 2013; 
Domcke et al., 2015), but can also bind to methylation without having repressive activity (Figure 
1.2.A-C) (Spruijt and Vermeulen, 2014). Finally, mC and its oxidized forms are bound specifically 
by several classes of proteins referred to as ‘readers’ of methylation, which can in turn recruit 
other chromatin-modifying proteins to DNA amongst other diverse functions (Spruijt et al., 2013). 
These studies have made it apparent that DNA methylation is an integral and dynamic part of 
chromatin and transcriptional regulation, far from its originally presumed role as a simple 
transcriptional repressor. 
 
Readers of DNA methylation 
The readers of methylation are a key component of epigenetic regulation as they function 
at the intersection of several critical mechanisms that affect transcriptional regulation. The reader 
proteins include the methyl-CpG binding domain (MBD), Kaiso, and SET- and Ring finger-
associated (SRA) domain and other protein families, some of which have cell-type specificity 
(Filion et al., 2006; Hendrich and Bird, 1998; Prokhortchouk et al., 2001; Spruijt et al., 2013; 
Unoki et al., 2004). The readers of methylation may induce transcriptional silencing by blocking 
transcription or other activating protein factors from binding to DNA (Figure 1.2.D), or by inducing 
chromatin remodeling through their binding partners (Du et al., 2015). However, there is evidence 
that readers of methylation, particularly certain MBD proteins, are also found at actively 
transcribed genes in promoters or intragenic sites, although the effect of this binding on 
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transcriptional regulation is not fully understood (Baubec et al., 2013; Günther et al., 2013) 
(Figure 1.2.E,F). These findings show that the readers of methylation and its derivatives are 
dynamic and developmentally regulated and therefore are essential to our understanding of 
epigenetic processes. Despite many biochemical studies on proteins that bind to methylation, the 
precise functions of these proteins in vivo remain unclear. In particular, the functions of the MBD 
family of proteins have been of great interest because these proteins have been genetically linked 
to disease in both humans and mouse models (Du et al., 2015). 
 
The methyl-CpG binding domain family of proteins 
Of the DNA methylation readers, the methyl-CpG binding domain (MBD) family 
represents a group of proteins that generally act as intermediates between methylation and other 
chromatin and histone modifying protein complexes. Members of the MBD protein family are 
essential for varied biological processes, such as embryogenesis and brain function and have 
been studied in human patients and animal models (Amir et al., 1999; Du et al., 2015; Hendrich et 
al., 2001). The first MBD protein identified was MeCP2 (Lewis et al., 1992), after which six 
additional proteins containing the conserved MBD were described to make up the canonical MBD 
family (Figure 1.3) (Baymaz et al., 2014; Hendrich and Bird, 1998). An additional four proteins, 
SETDB1/2 and BAZ2A/B, contain a phylogenetically distinct MBD and are therefore not included 
in the MBD family (Hendrich and Tweedie, 2003). The non-MBD readers of methylation recognize 
mCG through other protein domains, such as the SRA domain or zinc finger domains in Krüppel 
or Kaiso-related proteins (Filion et al., 2006; Prokhortchouk et al., 2001; Spruijt et al., 2013; Unoki 
et al., 2004).  
Despite the name, in fact not all members of this family bind to mCG with exclusivity, or 
at all. Instead, the MBD proteins have distinct DNA-binding properties that may contribute to their 
respective functions. Early studies showed that only certain MBD proteins, including MeCP2, 
MBD1, MBD2 and MBD4, are localized to hypermethylated major satellite regions (Hendrich and 
Bird, 1998; Nan et al., 1997). More detailed biochemical analysis demonstrated that all the MBD 
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proteins, with the exception of MBD3, MBD5, and MBD6, bind with high affinity to mCG 
(Hashimoto et al., 2012a). It was later shown that MBD1 is the only MBD protein with 
demonstrated affinity for unmodified cytosines, which is mediated through two or three 
alternatively spliced CxxC-type zinc finger domains (Jørgensen et al., 2004). MBD4 binds to 
methylated DNA and has DNA glycosylase activity that is unique in the MBD family (Hashimoto et 
al., 2012b). The most recently described MBD proteins, MBD5 and MBD6, are localized at 
pericentric heterchromatin but do not specifically bind methylated DNA (Laget et al., 2010). 
Whether or not any MBD proteins can specifically bind to hmC has been a source of 
controversy; however, it seems that none bind to hmC preferentially over mCG or unmodified 
cytosine (Hashimoto et al., 2012a; Spruijt et al., 2013). MeCP2 was reported to bind hmC (Mellén 
et al., 2012), but a closer examination showed that MeCP2 specifically binds hmC at CpA, but not 
CpG, dinucleotides in addition to binding to methylation in CpG and CpA contexts (Gabel et al., 
2015; Guo et al., 2014). MBD3 has been linked to hmC and Tet protein function in ESCs, 
suggesting that MBD3 may be specifically targeted to hydroxymethylation (Yildirim et al., 2011). 
However, in vitro studies have not detected a specific interaction between MBD3 and hmC and 
instead show MBD3 binding to mC, hmC and unmodified C with relatively low, equal affinity 
(Hashimoto et al., 2012a; Spruijt et al., 2013).  
The MBD proteins were first described as mediators of transcriptional repression that 
bind to methylated DNA and recruit various chromatin-modifying or co-repressor protein 
complexes (Feng and Zhang, 2001; Nan et al., 1998; Ng et al., 1999, 2000). However, only 
MeCP2, MBD1, and MBD2 fit this model precisely by recruiting co-repressor complexes through 
their transcriptional repression domains (TRDs) (Figure 1.3). Additionally, each of these proteins 
has distinct functions. Both MBD2 and MBD3 are part of the nucleosome remodeling and histone 
deacetylation (NuRD) protein complex (Feng and Zhang, 2001; Le Guezennec et al., 2006). 
However, MBD2 binds to mCG while MBD3 has a point mutation in the MBD that abolishes 
specific binding to methylated DNA (Saito and Ishikawa, 2002). MeCP2 associates with the 
Sin3A, coREST and NCoR co-repressor complexes, but has also been linked to heterochromatin 
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formation, long-range chromatin looping, and alternative splicing (Agarwal et al., 2007; Ballas et 
al., 2005; Ebert et al., 2013; Kernohan et al., 2014; Lyst et al., 2013; Maunakea et al., 2013; Nan 
et al., 1998). MBD1 functions in transcriptional repression and replication-dependent 
heterochromatin formation (Fujita et al., 2003b, 2003c; Ng et al., 2000). Therefore, although 
MeCP2, MBD1 and MBD2 are superficially similar, these proteins have distinctive DNA binding 
properties, protein associations, and functions, and should be considered separately but in 
context of each other. In this study, we have focused on MBD2 with the goal of characterizing 
MBD2 in vivo functions through phenotypic, molecular, and gene expression analyses. 
 
MOLECULAR FUNCTIONS OF MBD2 
 
Evolutionary origins of MBD proteins 
 MBD2 and MBD3 are the two most closely related mammalian MBD proteins, with 
identical genomic structure and over 70% identical amino acid sequences (Hendrich et al., 1999). 
These two MBD proteins presumably arose through a gene duplication event approximately 
concurrent with the separation of the ancestral vertebrate lineage. They also likely correspond to 
the ancestral MBD protein because the single MBD2/3 form found in invertebrates is the only 
MBD-containing protein identified in this lineage. The other MBD proteins are unique to 
vertebrates and either arose from further gene duplication events of the ancestral MBD2/3, or 
from an orphan MBD-like protein (Hendrich and Tweedie, 2003). The functions of MBD2/3 are 
highly conserved from invertebrates to vertebrates with some important distinctions. For example, 
the Drosophila melanogaster MBD2/3 orthologue interacts with components of the NuRD 
complex to mediate transcriptional repression (Ballestar et al., 2001), but binds preferentially to 
mCH instead of mCG (Marhold et al., 2004). There is also some variation amongst vertebrates in 
the number and structure of the MBD2/3 genes. The African clawed frog (Xenopus laevis) and 
zebrafish (Danio rerio) each have two forms of MBD3, one of which does bind mCG, and one 
form corresponding more closely to mammalian MBD2 (Hendrich and Tweedie, 2003; Wade et 
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al., 1999). In contrast, mammals have one MBD2 gene with methylation-specific binding 
capability and one MBD3 gene that does not bind to methylation, each with several alternatively 
spliced or translated isoforms (Hendrich et al., 1999; Hendrich and Bird, 1998).  
 
MBD2 gene and protein structure 
Mammalian MBD2 was identified in a search for proteins containing the conserved MBD 
(Hendrich and Bird, 1998). MBD2 and MBD3 are on different chromosomes in humans and mice, 
but have a highly similar genomic structure, further indicating the occurrence of an ancestral gene 
duplication event (Hendrich et al., 1999; Hendrich and Tweedie, 2003). Murine MBD2 is encoded 
by six coding and one non-coding exons, with the MBD spanning exons 2 and 3, and has three 
isoforms: MBD2a, MBD2b, and MBD2c (also known as MBD2t) (Figure 1.4.A) (Hendrich et al., 
1999; Hendrich and Bird, 1998). The distinctions between the isoforms of MBD2 correspond to 
different functions, and are therefore critical for the understanding of MBD protein function in vivo. 
MBD2a and MBD2b arise from two alternative translation start sites and differ only in the 
inclusion of a GR-rich N-terminal domain in MBD2a (Figure 1.4.B). Both isoforms contain the full 
MBD and C-terminal TRD, which is essential for MBD2 interactions with co-repressor protein 
complexes, including the NuRD complex (Boeke et al., 2000). 
The inclusion of the GR-rich domain in MBD2a may have important functional 
consequences, as post-translational methylation of this region affects interactions with DNA and 
NuRD (Tan and Nakielny, 2006). Furthermore, the GR-rich domain also mediates MBD2 
interactions with RNA (Jeffery and Nakielny, 2004). MBD2a protein consistently appears as a 
doublet in western blot analyses, suggesting that a fourth alternatively spliced, translated, 
modified, or cleaved isoform may be present (Ng et al., 1999). The C-terminal TRD region of 
MBD2 includes two domains that interact with different members of the NuRD complex. The 
intrinsically disordered region immediately downstream of the MBD interacts directly with the 
NuRD components RBBP4/7, HDAC1/2 and MTA1/2/3 (Desai et al., 2015), while a coiled-coil 
domain mediates interactions with p66α and p66β (later renamed GATAD2a and GATAD2b) 
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(Feng and Zhang, 2001; Gnanapragasam et al., 2011). The third isoform, MBD2c or MBD2t, 
utilizes an alternative third exon and produces a truncated protein that includes the N-terminal 
GR-rich domain and the MBD, without the C-terminal TRD (Figure 1.4.B) (Hendrich and Bird, 
1998). This isoform is expressed exclusively in the testes and ESCs and does not interact with 
the NuRD complex, with important functional consequences particularly for pluripotent stem cells 
(Baubec et al., 2013; Hendrich and Bird, 1998; Lu et al., 2014). 
 
MBD2 and NuRD 
 MBD2 was first described as part of a methylation-binding protein named MeCP1 
(Meehan et al., 1989), which was later resolved to be the components of the NuRD complex in 
addition to MBD2 (Ng et al., 1999; Zhang et al., 1999). The composition and functions of the 
NuRD complex are conserved from mammals to other vertebrates and insects (Marhold et al., 
2004; Wade et al., 1999). NuRD consists of the ATP-dependent remodeling enzymes CHD3/4, 
histone deacetylases HDAC1/2, histone chaperones RBBP4/7, and DNA binding proteins 
GATAD2A/B and MTA1/2/3 in addition to MBD2 and MBD3 (Torchy et al., 2015). NuRD has both 
ATP-dependent nucleosome remodeling and histone deacetylase activity (Basta and Rauchman, 
2015). Early studies of MBD protein function focused on the transcriptional repressive activities of 
NuRD. The first model of MBD2 function proposed that MBD2 recruits NuRD to methylated sites 
to induce histone-deacetylase-dependent transcriptional silencing and chromatin compaction 
(Figure 1.5.A) (Ng et al., 1999). In this simplified model, reduced DNA methylation density 
corresponds to less MBD2/NuRD binding activity, increased histone acetylation and more open 
chromatin allowing for active transcription (Figure 1.5.B). This activity was observed in numerous 
studies examining repression of methylated reporter constructs and endogenous methylated 
promoters of several genes, particularly those related to cancer (Auriol et al., 2005; Chatagnon et 
al., 2009; Feng and Zhang, 2001; Ng et al., 1999; Ramírez et al., 2012). 
 Despite the biochemical evidence for this model of MBD2/NuRD mediated transcriptional 
repression, many studies now suggest that this model does not constitute the full activity of 
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MBD2/NuRD. NuRD unexpectedly has both repressive and activating effects on transcription, 
and may be better described as a modulator of transcriptional activity (Reynolds et al., 2013). 
Furthermore, it has been challenging to identify specific methylated genes that are targeted for 
regulation by MBD2 when studying transcriptome changes on a genome-wide scale. Upon loss of 
MBD2, both upregulation and downregulation occurs and it is difficult to distinguish direct from 
indirect effects, implying that MBD2-mediated transcriptional regulation may be context-specific 
(Günther et al., 2013; Lopez-Serra et al., 2008; Stefanska et al., 2013). By correlating MBD2 
binding sites determined by chromatin immunoprecipitation (ChIP) with differentially expressed 
genes upon knockdown of MBD2, several studies support the model that loss of MBD2 primarily 
results in derepression of lowly expressed genes (Devailly et al., 2015; Günther et al., 2013).  
One possible explanation for the subtle gene regulation by MBD2 is that the interactions 
between MBD2 and NuRD are more complicated than originally realized. This may be due to 
different isoforms of MBD2, of which only two interact with NuRD, and post-translational 
modifications of MBD2 that can also affect NuRD interactions (Baubec et al., 2013; Tan and 
Nakielny, 2006). Recent findings are in opposition to the original model which proposed that 
MBD2 recruits NuRD to methylated sites (Ng et al., 1999). Surprisingly, NuRD shows less than 
expected co-occupancy with MBD2 at methylated regions (Figure 1.6.A). MBD2 is also found at 
unmethylated, active regions and requires interaction with the NuRD complex for this localization 
(Baubec et al., 2013). These findings suggest NuRD is recruiting MBD2 to unmethylated sites 
where it would otherwise not bind (Figure 1.6.B). It is plausible that MBD2b, which has the C-
terminal TRD, interacts with NuRD and methylated and unmethylated DNA in a similar manner to 
MBD2a (Figure 1.6.C,D). In contrast, MBD2c, which does not interact with NuRD due to the 
absence of the TRD, may still bind methylated sites without NuRD but is absent from 
unmethylated sites (Figure 1.6.E,F) (Baubec et al., 2013). These findings support the view that 
MBD2, through its interactions with NuRD, may be involved in transcriptional activation as well as 
repression (Baubec et al., 2013; Reynolds et al., 2013). 
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The other critical factor that may be affecting MBD2 function is the role of MBD3 in 
complex with NuRD. MBD3 was identified as an essential member of the NuRD complex with 
transcriptional repressive activity, despite not binding to methylated DNA (Wade et al., 1999). 
Two further studies gave strong indication that MBD2 and MBD3 may have very different 
molecular functions in vivo. First, NuRD incorporates MBD2 or MBD3 into mutually exclusive 
complexes (Le Guezennec et al., 2006) and second, genetic studies of mice show distinctly 
different null phenotypes for each gene (Hendrich et al., 2001). MBD3 is considered to be a core 
NuRD component with repressive activity (Morey et al., 2008; Saito and Ishikawa, 2002; Wade et 
al., 1999), but its exact functions within NuRD and the functional mechanisms of NuRD assembly 
with either MBD2 or MBD3 are unknown. 
It is clear that MBD2/NuRD and MBD3/NuRD have distinct genome-wide distributions 
(Baubec et al., 2013; Günther et al., 2013) and different functions, particularly in ESCs (Gu et al., 
2011; Kaji et al., 2006; Lu et al., 2014). Together these findings suggest that transcriptional 
regulation by MBD2 is more dynamic and multifaceted than originally proposed, and this may 
help explain why direct targets of MBD2 regulation have been difficult to identify in vivo. Further 
work is required to determine the dynamics of MBD2, MBD3 and NuRD recruitment to chromatin 
and how MBD2 may function within and also independently of NuRD. 
 
MBD2 and other protein complex interactions 
 Although MBD2 is usually associated with the NuRD co-repressor complex, there is 
increasing evidence that MBD2 functions may rely on interactions with several other diverse 
protein complexes. Several of these interactions directly affect MBD2 binding to NuRD, and it is 
possible that they also mediate NuRD-independent functions. The most well described example 
is the post-translational methylation of MBD2 by PRMT1 and PRMT5 (Le Guezennec et al., 2006; 
Tan and Nakielny, 2006). Methylation of the N-terminal RG-rich region of MBD2a (Figure 
1.7.A,B), and presumably MBD2c although this has not been shown directly (Figure 1.7.C,D), 
reduces the affinity of MBD2 for the NuRD complex and for methylated DNA. Importantly, these 
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interactions are MBD2-specific because no PRMT proteins are associated with MBD3/NuRD (Le 
Guezennec et al., 2006). Methylation of histone H4 by PRMT1 or PRMT5 produces 
transcriptionally active or repressed chromatin, respectively (Nicholson et al., 2009). It is unknown 
if either PRMT protein modifies chromatin in addition to MBD2 where MBD2/NuRD is bound, or if 
these functions are independent from each other.  
There is also evidence that MBD2 interacts with other chromatin- or transcription-
regulating protein complexes besides NuRD. MBD2 can form a complex with TACC3 and the 
histone acetyltransferase pCAF to activate transcription (Angrisano et al., 2006). Another study 
showed that MBD2a, but not MBD2b, reactivates transcription of unmethylated, cAMP-responsive 
genes through interactions with RNA helicase A, part of the CREB transcriptional coactivator 
complex (Fujita et al., 2003a). Interestingly, when MBD2 is associated with either of these protein 
complexes it is not bound to histone deacetylases, which are key components of the NuRD 
complex. It is not clear if these interactions represent additional NuRD-independent functions of 
MBD2, or if they only serve to mediate MBD2-NuRD interactions.  
Finally, there is evidence that MBD2 has a role in cell cycle progression. MBD2 was 
found to associate with the transcription factor histone nuclear factor P (HiNF-P, also known as 
MIZF), which regulates transcription of histone H4 genes at the G1/S phase transition (Mitra et 
al., 2003; Sekimata et al., 2001). Another group found that MBD2 immunoprecipitates with and 
co-localizes with DNMT1 at replication foci (Tatematsu et al., 2000). However, a more recent 
study demonstrated that MBD2 and other MBD proteins are delayed in their recruitment to 
chromatin after DNA replication, as opposed to binding concurrently or soon after replication 
(Alabert et al., 2014). Further work is necessary to resolve the many remaining questions 
surrounding the mechanisms of MBD2 function both in association with and independent of the 
NuRD complex. The majority of studies on MBD2 protein complex interactions have been 
performed in cell culture systems, and there is little information on these mechanisms in a 
relevant biological context. 
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DNA binding properties and genome-wide localization of MBD2 
Several MBD proteins have different DNA-binding properties that may be related to their 
different functions in vivo, such as MeCP2 binding to non-CpG methylation, which is abundant in 
neurons (Gabel et al., 2015). MBD2 binds specifically to mCG, and there has been no 
demonstrated affinity for methylation in mCH contexts, hmC or unmodified cytosine (Hashimoto et 
al., 2012a; Spruijt et al., 2013). Interestingly, MBD2 also binds to mRNA and siRNA with high 
affinity in an MBD-independent manner through its basic N-terminal RG repeats in vitro (Jeffery 
and Nakielny, 2004). One candidate for regulation by MBD2 is the lncRNA Xist, which is de-
repressed in the absence of MBD2, but not other MBD proteins (Barr et al., 2007). However, this 
repression is maintained through transcriptional silencing of the methylated Xist locus, and it is 
unknown if MBD2 also interacts with the Xist lncRNA directly. 
 The binding of MBD2 to methylated sites depends on the presence of an intact MBD and 
the methylating activities of the DNMT proteins (Baubec et al., 2013). Several studies have 
examined MBD2 binding to specific loci such as the methylated regulatory regions of BRCA1 or 
Foxp3 (Auriol et al., 2005; Wang et al., 2013), but only a few attempts have been made to 
determine the genome-wide distribution of MBD2. These experiments are complicated by the fact 
that DNA methylation patterns are dynamic and cell-type specific (Schultz et al., 2015) and 
antibodies to MBD2 are generally unreliable; therefore all ChIP data to date have been acquired 
using cell culture or biochemical tagging approaches (Baubec et al., 2013; Chatagnon et al., 
2011; Devailly et al., 2015; Günther et al., 2013; Menafra et al., 2014). 
Studies in HeLa cells (Chatagnon et al., 2011; Günther et al., 2013), mouse ESCs 
(Baubec et al., 2013), and breast cancer cell lines (Devailly et al., 2015; Menafra et al., 2014) all 
showed that MBD2 localization is highly correlated with methylation, as expected, with no 
detectable sequence specificity. MBD2 is enriched at transcription start sites, promoters, and 
exons that coincide with methylated CGIs (Baubec et al., 2013; Günther et al., 2013; Menafra et 
al., 2014). Highly methylated sites that have low mCG density, such as most repetitive regions 
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and low-CpG promoters, introns and intergenic regions, show low or no enrichment for MBD2 
(Baubec et al., 2013; Günther et al., 2013).  
Surprisingly, MBD2 was also detected at unmethylated sites including intermediate- and 
high-CpG promoters that correlate with the presence of activating histone marks. The MBD2c 
isoform, which lacks the C-terminal region that interacts with NuRD, was lost from these regions 
but retained at methylated sites, which suggests that MBD2 localization to unmethylated sites is 
NuRD-dependent. MBD2 binding to unmethylated promoters is also associated with tissue-
specific regulatory regions and low levels of gene expression (Baubec et al., 2013; Günther et al., 
2013; Menafra et al., 2014). 
In contrast, MBD3 binding, similar to NuRD, is not correlated with methylation and 
instead is enriched at transcriptionally active, open chromatin (Baubec et al., 2013; Günther et al., 
2013). Despite evidence from several studies that MBD2/NuRD and MBD3/NuRD are localized at 
active chromatin, biochemical evidence shows that NuRD is repelled by the activating histone 
mark H3K4me3 (Eberl et al., 2013).  Therefore, the mechanisms of MBD2/NuRD recruitment and 
distribution on chromatin remain poorly understood. Additionally, the dynamics and biological 
consequences of NuRD formation with either MBD2 or MBD3 are unclear, particularly in the in 
vivo cellular context. 
 
BIOLOGICAL FUNCTIONS OF MBD2 
 
Neuronal functions of the MBD protein family 
 Epigenetic mechanisms in the brain are distinctive because DNA methylation changes 
dynamically throughout development and in learning and memory processes (Heyward and 
Sweatt, 2015; Lister et al., 2013; Szulwach et al., 2011). The highly complex network of diverse 
neuronal subtypes have distinct epigenomic and transcriptional profiles (Mo et al., 2015), further 
suggesting that epigenetic regulation is essential for the maintenance and function of the brain. 
Most MBD proteins are associated with neuronal functions in both humans and mice. The most 
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well studied example is MECP2, which when mutated, deleted, or duplicated causes the 
neurodevelopmental disorder Rett syndrome (Amir et al., 1999; Pohodich and Zoghbi, 2015). 
Loss of MBD5 is the causative factor in 2q23.1 microdeletion syndrome, characterized by 
intellectual disability, behavioral problems and seizures (Talkowski et al., 2011). Mutations in the 
other MBD proteins have not been definitively shown to cause specific disorders in humans, but 
have been correlatively linked to autism spectrum disorder (ASD) (Cukier et al., 2010, 2012; Li et 
al., 2005).  
Mouse models with deletion of Mecp2 or Mbd5 closely recapitulate the symptoms of the 
respective human disorders, reflecting the conserved functions of these proteins (Camarena et 
al., 2014; Guy et al., 2001). Mice with mutation, deletion or duplication of Mecp2 show changes in 
many phenotypes associated with the human disorder, including decreased anxiety-related 
phenotypes, impaired motor ability, reduced sociability, deficits in learning and memory, seizures, 
respiratory abnormalities, and premature lethality (Bissonnette et al., 2014; Goffin et al., 2012). 
Mice with loss of Mbd1 show many of the same phenotypes as Mecp2 mice that are commonly 
associated with ASDs in humans, including changes in anxiety-related phenotypes, decreased 
sociability and impaired learning and memory (Allan et al., 2008; Zhao et al., 2003).  
Furthermore, the NuRD complex and MBD3 also have important neuronal functions. 
Mbd3 constitutive null mice are embryonic lethal (Hendrich et al., 2001), but a Mbd3 brain-specific 
conditional null mouse has defects in cortical thickness and neuronal differentiation and is 
neonatal lethal (Knock et al., 2015). In addition, a recent study identified a brain-specific isoform 
of the NuRD component CHD5 which interacts with MBD3, but not MBD2, which suggests that 
MBD3 has brain-specific functions distinct from MBD2 (Potts et al., 2011). The NuRD complex is 
also essential in the brain. Genetic deletion of NuRD complex component CHD4, which disrupts 
the NuRD complex, affects gene expression programs in the cerebellum that regulate synaptic 
differentiation (Yamada et al., 2014).  
In contrast to the relatively severe phenotypes of the other MBD protein null mice, Mbd2 
null mice are viable and fertile and the only reported behavioral phenotype is a maternal nurturing 
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deficit (Hendrich et al., 2001). It has been speculated that MBD2 may also have brain-specific 
functions judging by the essential role of the other closely-related MBD proteins in the brain (Du 
et al., 2015). A role for MBD2 in several other peripheral cell types have reported, including 
embryonic stem cells and various cells of the immune system, but the effect of these functions on 
any phenotypes of Mbd2 mice have not been fully characterized (Cook et al., 2015; Lu et al., 
2014; Wang et al., 2013). 
 
Isoform-specific roles of MBD2 in pluripotent cells 
 The maintenance, proliferation and differentiation of pluripotent cells is highly dependent 
on epigenetic mechanisms (Meissner, 2010). It is clear that MBD3 has an essential role in 
pluripotent ESCs because Mbd3 null mice are early embryonic lethal (Hendrich et al., 2001). In 
contrast, mice with loss of each other MBD protein are viable, albeit with a range of phenotypic 
severity (Du et al., 2015). Recent work has revealed an important role for MBD2 in pluripotent 
cells. MBD2 is more lowly expressed in ESCs compared to MBD3 (Lu et al., 2014) and was 
initially thought to repress reprogramming of somatic to induced pluripotent stem (iPS) cells (Lee 
et al., 2013). However, further efforts found that differentially spliced isoforms of MBD2 actually 
have a role in both repression and promotion of reprogramming to pluripotency in human 
pluripotent stem cells (hPSCs) (Lu et al., 2014). MBD2a, the longest isoform that includes both 
the N-terminal GR-rich domain and C-terminal TRD, is specifically enriched in differentiated 
fibroblasts (DFs) while alternatively spliced MBD2c, which lacks the TRD, is enriched in hPSCs. 
Overexpression of MBD2a in hPSCs disrupts pluripotency presumably by mediating NuRD 
targeting to the OCT4 and NANOG promoter regions and downregulating their expression. In 
contrast, MBD2c is also bound at these promoters but does not interact with NuRD. 
Overexpression of MBD2c together with other reprogramming factors in DFs actually enhances 
reprogramming efficiency. The authors conclude that MBD2a and MBD2c mediate the balance 
between proliferation and differentiation of hPSCs (Lu et al., 2014). 
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 It is unclear why Mbd2 constitutive null mice are viable and fertile when there is a role for 
MBD2 and NuRD in pluripotent cells (Hendrich et al., 2001; Lu et al., 2014; Reynolds et al., 
2012). Similarly to the brain, it is possible that MBD3 may be sufficient to mediate NuRD-related 
functions during embryogenesis. However, a genetic interaction between Mbd2 and Mbd3 argues 
that MBD3 cannot fully compensate for loss of MBD2 (Hendrich et al., 2001). The role of MBD3 in 
pluripotent cells has been better studied but is not fully understood. MBD3-deficent blastocysts 
fail to develop mature epiblast after implantation, accompanied by significant gene expression 
changes, suggesting that MBD3 is required for differentiation (Kaji et al., 2006, 2007). These 
findings were supported by a study that showed that NuRD, with MBD3, is required to 
dynamically regulate expression of pluripotency genes in ESCs in order to transition to 
differentiation (Reynolds et al., 2012). The function of MBD3 in reprogramming of differentiated 
somatic cells to iPS cells has been controversial. Two studies found that removal of NuRD 
increased reprogramming efficiency (Luo et al., 2013; Rais et al., 2013), while another study 
supports that NuRD is essential for reprogramming (Dos Santos et al., 2014). These conflicting 
results suggest that MBD3/NuRD may have different context-specific effects on differentiation, 
but further studies are needed to resolve this question.  
 
Emerging roles for MBD2 in immunity 
 There is strong evidence that DNA methylation and other epigenetic mechanisms are 
essential in hematopoiesis and differentiation of myeloid and lymphoid cell lineages (Álvarez-
Errico et al., 2014; Shih et al., 2014). For example, CD4+ T cells undergo extensive 
transcriptional, chromatin remodeling and DNA methylation changes during maturation (Komori et 
al., 2015). NuRD, MBD2 and MBD3 have roles in multiple lymphoid cell populations (Dege and 
Hagman, 2014a). The core NuRD component CHD4 is required for the maintenance and 
differentiation of hematopoietic stem cells (Yoshida et al., 2008). However, a specific role for 
MBD2 in these cells and other early progenitors has not been described. Mbd2 null mice have 
unaltered lymphoid organs and major lymphocyte subsets, suggesting that MBD2 may not be 
 
 17 
required at early stages of hematopoiesis (Hutchins et al., 2002). In B cells, the NuRD complex 
interacts with various transcription factors to mediate temporal changes in development and 
differentiation (Gao et al., 2009; Musselman et al., 2012). Transcriptional regulation of the B-cell 
specific Cd79a gene involves MBD2-dependent CHD4/NuRD recruitment, but whether B cells are 
broadly affected in Mbd2 null mice is unknown (Ramírez et al., 2012). 
 The functions of NuRD and MBD2 in several T cell populations have been studied more 
extensively. Loss of MBD2 has been linked to changes in proliferation or maturation of multiple T 
cell populations. These changes may arise from altered expression of several critical factors, 
some of which are controlled by differentially methylated regulatory regions. For example, loss of 
MBD2 or NuRD components CHD4 or MTA2 skews CD4+ T cell polarization towards Th2 
populations, with implications for pathogen resistance (Hosokawa et al., 2013; Hutchins et al., 
2002, 2005; Lu et al., 2008). One study proposed that these changes may occur because 
MBD2/NuRD regulates expression from the Th2 cytokine locus, which is demethylated during 
Th2 cell differentiation (Aoki et al., 2009). 
Interestingly, MBD2 also indirectly affects CD4+ T cell maturation by regulating gene 
expression programs in dendritic cells, which are required to direct T helper cell maturation (Cook 
et al., 2015). The maturation of CD8+ T cell populations into effector and memory cells after 
acute viral infection is also directly affected by loss of MBD2, consistent with MBD2 regulating 
expression of surface markers and cytokines (Kersh, 2006). Finally, MBD2 regulates the 
expression of the master T regulatory (Treg) cell transcription factor Foxp3 (Lal et al., 2009; 
Wang et al., 2013). MBD2 binds to a Treg-specific demethylation region (TSDR) upstream of 
Foxp3 that becomes demethylated in thymus-derived natural Tregs. MBD2 promotes the Tet2-
mediated demethylation of the TSDR in Treg cells. Consequently, Mbd2 null mice show 
decreased Treg numbers and impaired Treg suppressive function in addition to retaining 
methylation at the TSDR (Wang et al., 2013). 
Disruptions to the NuRD complex are detrimental to immunity, as evidenced by a study 
that showed mice with loss of MTA2 develop a severe lupus-like autoimmune disease (Lu et al., 
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2008). Although loss of MBD2 results in reduced numbers of Treg cells, Mbd2 null mice 
surprisingly do not develop autoimmunity possibly because their T effector cells are less 
responsive to stimulation and more susceptible to Treg suppression (Wang et al., 2013). In fact, 
loss of MBD2 is protective against experimental autoimmune encephalomyelitis, a model of T cell 
mediated autoimmunity and demyelinating diseases of the central nervous system (Zhong et al., 
2014). In human patients, increased levels of MBD2 and global demethylation in CD4+ T cells 
has been observed in several autoimmune disorders, including systemic lupus erythematosus 
(Balada et al., 2007; Liu et al., 2011), systemic sclerosis, dermatomyositis (Lei et al., 2009) and 
MBD2 was determined to be a susceptibility locus for psoriasis (Tsoi et al., 2012). These human 
and mouse studies point to MBD2/NuRD being an essential regulator of immune function with 
therapeutic potential. However, considerable effort is required to fully understand the complexities 
of MBD2 function in immunity at the cellular and systemic levels.  
 
Implications for MBD2 function in cancer 
 Factors that shape the epigenome have been studied extensively in regards to cancer 
initiation, progression and treatments (Baylin and Jones, 2011). The NuRD complex is thought to 
mediate tumorigenesis by modifying expression or activities of transcription factors linked to 
cancer, targeting hypermethylated tumor suppressor genes for transcriptional silencing, and 
maintaining genomic stability (Lai and Wade, 2011). Many studies have attempted to link loss of 
MBD2 or MBD3 to significantly increased cancer predisposition in human patients, but evidence 
for this is limited. Studies of MBD2 and MBD3 in cancer have therefore focused on their potential 
as therapeutic targets. However, concerns have been raised regarding the feasibility of directly 
targeting these proteins and possible off-target effects (Parry and Clarke, 2011). 
 MBD2 has been studied particularly in the context of colorectal cancer, but questions 
remain as to the specific role of MBD2 in tumor initiation or progression. MBD2 is required for 
regulation of gene expression in the gastrointestinal tract, as Mbd2 null mice show altered spatial 
expression of several genes in the small intestine and colon (Berger et al., 2007). Loss of MBD2 
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is protective against tumorigenesis specifically in ApcMin/+ mice, a mouse model of sporadic 
colorectal tumorigenesis (Sansom et al., 2003). The ApcMin/+mouse develops tumors due to 
significantly upregulated Wnt signaling (Sansom, 2004), which is downregulated in the absence 
of MBD2 (Phesse et al., 2008). While these results suggest targeting MBD2 may have 
therapeutic potential for colorectal cancer, further investigations show that the downregulation of 
Wnt signaling may not be related to MBD2-specific functions. First, Mbd2 null mice in a wildtype 
background do not show any changes in intestinal histology or Wnt signaling (Phesse et al., 
2008). More importantly, similar downregulation of Wnt signaling and reduced tumorigenesis 
occurs when perturbing several other chromatin binding or modifying factors, including the 
DNMTs (Cai et al., 2014), the methylation-binding protein Kaiso (Prokhortchouk et al., 2006), and 
the chromatin remodeling factor Brg1 (Holik et al., 2014). In contrast, MBD3 is more likely to have 
a direct function in the gastrointestinal tract. Loss of MBD3 specifically in the gut results in 
increased tumorigenesis induced by inflammation through the upregulation of targets of the AP-1 
transcription factor (Aguilera et al., 2011). It is currently unknown if these pathways are also 
affected by loss of MBD2. 
MBD2 may directly affect tumorigenesis because reduced expression of MBD2 inhibits 
tumor growth in cultured cell lines and in human cancer cell xenografts in mice (Campbell et al., 
2004). One way this could occur is through the de-repression of tumor suppressor genes. MBD2 
binds to hypermethylated promoters of tumor suppressor genes and contributes to their 
transcriptional silencing, which has been shown to occur in multiple human cancer cell lines 
(Lopez-Serra et al., 2008). Therefore, loss of MBD2 may be protective against tumorigenesis by 
relieving transcriptional repression of hypermethylated tumor suppressor genes such as 
p14(ARF) and p16(INK4A) that commonly show aberrant methylation in colon cancer cells 
(Magdinier and Wolffe, 2001; Martin et al., 2008). Similar mechanisms have been observed in 
glioma cells (Zhu et al., 2011) and breast cancer cells (Mian et al., 2011). 
Interestingly, MBD2 has been shown to directly repress human telomerase reverse 
transcriptase (hTERT) in several cancer cell types (Chatagnon et al., 2009). hTERT is usually 
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hypermethylated and silenced, but is expressed in most cancer cells and therefore, in regards to 
this mechanism, loss of MBD2 may encourage tumor growth. However, loss of MBD2 has 
complex effects on gene expression with both upregulation and downregulation of many genes in 
breast cancer and liver cancer cell lines (Devailly et al., 2015; Stefanska et al., 2013). 
Downregulation of certain genes in the absence of MBD2 may be protective against 
tumorigenesis. In prostate cancer cells, loss of MBD2 suppresses tumor growth through 
hypermethylation and silencing of pro-metastatic genes (Shukeir et al., 2006). These complexities 
indicate that identification and manipulation of specific therapeutic pathways targeted via MBD2 
will be challenging. Furthermore, the majority of these studies have identified misregulation of a 
single locus in cultured cells and do not fully address the role of MBD2 in a biological, cellular 
context. 
Studies of MBD2 in human cancer patients also point to MBD2 as a potential regulator of 
tumorigenesis. The finding that the 18q21 locus that includes Mbd2 is deleted in 70% of human 
colorectal cancers (Fearon et al., 1990) led to speculation that Mbd2 could be a candidate tumor 
suppressor gene itself. However, further investigation showed that only the deleted in colon 
cancer (DCC) gene at this locus is likely to be directly linked to cancer progression. All other 
neighboring genes, including Mbd2, are rarely affected by hypermethylation or point mutations in 
colorectal cancer (Bader et al., 2003; Derks et al., 2009). Mbd3 is also generally unaffected by 
mutations or epigenetic changes in colon cancer (Zhu et al., 2004). 
Despite the absence of mutations in MBD2 or MBD3 in cancer patients, there is evidence 
that these genes show altered regulation in tumors. Both MBD2 and MBD3 are downregulated in 
multiple human tumor types, but it is not clear what effect this has on tumor progression (Kanai et 
al., 1999; Müller-Tidow et al., 2001; Pontes et al., 2014). Studies of MBD2 in breast cancer have 
produced conflicting results. One study found that MBD2 is upregulated in breast tumors (Billard 
et al., 2002), while another found no difference (Müller et al., 2003). Analysis of single nucleotide 
polymorphisms in Mbd2 and breast cancer were similarly difficult to interpret, although some 
weak associations were detected (Sapkota et al., 2014; Zhu et al., 2005). Because MBD2 
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appears to have variable or context specific effects on tumorigenesis, significant further 
investigations into the molecular mechanisms of MBD2 function must be undertaken to identify 
potential therapeutic targets associated with these functions.  
 
THE CHARACTERIZATION OF MBD2 FUNCTIONS IN VIVO 
 
 Of the MBD family proteins, considerable efforts have been made to understand the 
functions of MeCP2 because mutations in this protein are genetically linked to neurological 
disease (Pohodich and Zoghbi, 2015). MBD1, MBD3 and MBD5 have also been the subject of 
many mouse model studies with implications for brain development and embryogenesis 
(Camarena et al., 2014; Yildirim et al., 2011, 3; Zhao et al., 2003). In contrast, MBD2 functions 
have been examined almost exclusively using cultured cells (Feng and Zhang, 2001; Ng et al., 
1999). These studies have shed light on important biochemical attributes of MBD2, but the 
functions of MBD2 in vivo remain largely unexplored. 
Previous work has shown that Mbd2 null mice are viable and fertile with only a reported 
nurturing deficit (Hendrich et al., 2001). This scenario raises significant questions about MBD2 
function in vivo. It is surprising that MBD2 is the most highly conserved MBD protein in mammals 
with reported functions in immune and ESCs, yet in contrast to the other MBD proteins, loss of 
MBD2 does not result in overt or specific phenotypes (Cook et al., 2015; Lu et al., 2014; Wang et 
al., 2013). The most common explanation put forth for this observation is that the other MBD 
proteins are compensating for the loss of MBD2 functions. However, the fact that the MBD 
proteins have distinct DNA binding properties and protein associations does not support this 
hypothesis (Du et al., 2015). Even MBD3, arguably the best candidate for MBD2 compensation 
due to their common association with NuRD, has distinctly different DNA-binding properties and 
is unlikely to recapitulate the role of MBD2 (Baubec et al., 2013; Hendrich et al., 2001). Therefore, 
there likely remain many unrealized functions for MBD2 in vivo. Previous studies have pointed to 
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a role for MBD2 in immunity (Wang et al., 2013), the gastrointestinal system (Berger et al., 2007), 
and in tumorigenesis (Sansom et al., 2003), all with significant implications for human disease. 
In this study, we sought to expand our understanding of MBD2 in vivo functions with two 
parallel genetic approaches. First, we characterized multiple aspects of the Mbd2 null mouse 
phenotype, beginning with phenotypes that have been observed in other MBD protein null mice 
(Chapter 2) (Guy et al., 2001; Zhao et al., 2003). Second, in order to analyze MBD2 in vivo 
functions, we developed a novel transgenic mouse lines expressing biotin-tagged alleles of 
endogenous MBD2 and systematically compared the spatiotemporal expression of MBD2 in 
context of the other MBD proteins (Chapter 3). Together, this work identifies previously 
uncharacterized in vivo aspects of MBD2 function and new directions for further studies. 
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CHAPTER 1 FIGURES 
 
 
 
Figure 1.1. The cytosine modification cycle. 
Unmodified cytosine is methylated by the DNA methyltransferase proteins DNMT1, DNMT3A and 
DNMT3B. 5-methyl cytosine is oxidized by TET1, TET2, or TET3 to 5-hydroxymethylcytosine. 
Further oxidation of hydroxymethylcytosine by the TET proteins yields 5-formylcytosine and 5-
carboxylcytosine. 5-carboxylcytosine is converted to an unmodified cytosine by thymine-DNA 
glycosylases (TDG) and base excision repair (BER) pathways. 
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Figure 1.2. Models of DNA methylation affecting transcription factor recruitment. 
(A) The binding of transcription factors at hypomethylated regulatory regions drives transcriptional 
activation. (B) Activating transcription factors are blocked from binding to hypermethylated 
regulatory regions, resulting in transcriptional silencing. (C) Methylation-specific transcription 
factors may bind hypermethylated regulatory regions to activate transcription. (D) Methyl-CpG 
binding domain (MBD) proteins can bind mCG-dense regions and block transcription factor 
binding, leading to transcriptional silencing. MBD proteins may bind to actively transcribed genes 
at intragenic (E) or promoter (F) sites, but the effect of this binding on transcriptional regulation is 
unclear. 
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Figure 1.3. The methyl-CpG binding domain (MBD) family of proteins. 
All MBD family proteins contain a highly conserved methyl-CpG binding domain (blue box) in 
addition to other functional domains. The MBD of MBD3 has a point mutation (*) that abolishes 
methyl-CpG binding. MBD5 and MBD6 do not specifically bind methyl-CpG (lighter blue box). 
MeCP2, MBD1 and MBD2 contain C-terminal transcriptional repression domains (TRD) that 
interact with co-repressor protein complexes (orange box). MBD1 has CxxC-type zinc finger 
domains which mediate DNA binding. MBD2 has an N-terminal glycine/arginine rich domain 
(yellow box) and a C-terminal coiled-coil domain, which is also found in MBD3 (green box). The 
functions of MBD4 are mediated through a C-terminal glycosylase domain (red box). Both MBD5 
and MBD6 contain proline rich domains (tan box) while MBD5 has a PWWP motif (purple box) 
that binds methylated histones. 
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Figure 1.4. The isoforms of MBD2 contain different functional domains. 
(A) The Mbd2 transcript has seven exons, with non-coding regions (smaller gray box) in exons 1, 
6 and 7. Coding regions are contained in exons 1-6 (white and filled boxes). The methyl-CpG 
binding domain (MBD, blue box) is split between exons 2 and 3 with the glycine/arginine rich 
region (yellow box) in exon 1. There are two translation start sites corresponding to MBD2a and 
MBD2b, respectively. MBD2c includes an alternatively spliced exon (striped box) between exons 
2 and 3. (B) MBD2a utilizes the first translation start site and includes the G/R rich domain, MBD 
and C-terminal transcriptional repression domain (TRD). Translation of MBD2b excludes the N-
terminal G/R rich domain. MBD2c includes the alternatively spliced exon and does not contain the 
C-terminal TRD. 
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Figure 1.5. Simplified model of transcriptional regulation by MBD2 and NuRD. 
(A) MBD2 binds to mCG-dense regions as a component of the NuRD complex, which induces 
histone deacetylation and chromatin compaction (large arrows) leading to transcriptional 
silencing. (B) At transcriptionally active sites, MBD2/NuRD is replaced by histone 
acetyltransferases and activating transcription factors to induce histone acetylation and open, 
active chromatin. 
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Figure 1.6. DNA binding dynamics of MBD2 isoforms and NuRD. 
(A) MBD2a binds to methyl-CpG dense sites with the NuRD complex. (B) At unmethylated sites, 
MBD2 recruitment to DNA is dependent on interactions with NuRD through the C-terminal 
transcriptional repression domain (TRD). (C) Similarly to MBD2a, MBD2b binds to methyl-CpG 
dense sites with NuRD and may be recruited to unmethylated sites via interaction with NuRD (D) 
MBD2c lacks the C-terminal TRD and does not interact with NuRD. Therefore, MBD2c may bind 
methylated sites without NuRD (E) and, in this model, would not be recruited to unmethylated 
sites by NuRD (F). 
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Figure 1.7. DNA binding dynamics of MBD2 depend on post-translational modifications. 
(A) MBD2a and NuRD binding to methylated sites results in nucleosome remodeling (large 
arrows) and deacetylation, producing transcriptional silencing. (B) Post-translational methylation 
of the N-terminal glycine/arginine rich region of MBD2a by PRMT1/5 reduces the affinity of 
MBD2a for NuRD and methylated DNA and may not produce transcriptional repression. (C) 
MBD2c does not interact with the NuRD complex but does bind methylated DNA. It is not fully 
understood how this binding may affect transcriptional regulation. (D) MBD2c has the N-terminal 
G/R rich domain, but it is not clear if it is also methylated by PRMT1/5 and if this modification 
would affect DNA binding similarly to MBD2a. 
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CHAPTER 2: Phenotypic characterization of Mbd2 Null Mice 
 
Adapted from: Wood, K. H., Johnson, B. S., Welsh, S. A., Lee, J. Y., Cui, Y., Krizman, E., 
Brodkin, E. S., Blendy, J. A., Robinson, M. B., Bartolomei, M. S., Zhou, Z. Tagging methyl-CpG 
binding domain proteins reveals different spatiotemporal expression and supports distinct 
functions. Epigenomics. In Press. 
 
ABSTRACT 
 
 Methylation of cytosine is an epigenetic mark that is essential for many biological 
processes, including brain development and function. The methyl-CpG binding domain (MBD) 
family of proteins specifically bind methylated cytosines and recruit different co-repressor 
complexes to regulate transcription and chromatin state. Genetic studies have linked the MBD 
proteins MeCP2 and MBD1 to neurodevelopmental disorders related to autism spectrum disorder 
(ASD) in humans and mice. However, a role for MBD2 in the brain has not been described. In this 
study, we characterized the behavioral phenotypes of mice lacking MBD2. We found that, in 
contrast to MeCP2 and MBD1, Mbd2 null mice are largely similar to control littermates, with mildly 
altered home-cage activity, nesting and body weight. To further investigate these phenotypes, we 
examined gene expression changes in the striatum and hypothalamus of Mbd2 null mice and 
also quantified the levels of biogenic amines in the cortex and striatum. Our results show that a 
small number of genes show altered expression in the striatum and hypothalamus and that 
biogenic amine levels are equivalent to wildtype littermates. We conclude that, in contrast to the 
closely related proteins MeCP2 and MBD1, MBD2 appears to be dispensable for brain functions 
at the age that we examined. 
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INTRODUCTION 
 
 Epigenetic mechanisms, including DNA methylation, are essential for proper brain 
function. DNA methylation at CpG and CpH sites and hydroxymethylation change dynamically in 
the brain throughout development concurrently with maturation of synapses (Lister et al., 2013). 
In the mature brain, synaptic plasticity and learning and memory processes are dependent on 
epigenetic mechanisms (Feng et al., 2010; Heyward and Sweatt, 2015). Furthermore, epigenetic 
mechanisms are linked to the vast diversity of neuronal cell types, each with unique 
transcriptional programs and functional properties (Mo et al., 2015). 
Genetic studies of MBD proteins in humans and animal models have demonstrated a 
critical role for this protein family in the brain (Allan et al., 2008; Amir et al., 1999; Cukier et al., 
2010, 2012; Guy et al., 2001; Zhao et al., 2003). Mutations in several MBD proteins have been 
identified in individuals with autism spectrum disorder (ASD), although further work is needed to 
determine if these mutations are causative (Cukier et al., 2010, 2012). MeCP2 and MBD5 are 
linked to the specific neurological diseases Rett syndrome and 2q23.1 microdeletion syndrome, 
respectively (Amir et al., 1999; Talkowski et al., 2011), both of which are closely recapitulated in 
mouse models with deletion or mutation of each gene (Camarena et al., 2014; Goffin et al., 
2012). Mbd1 null mice also exhibit behavioral phenotypes that mimic features of ASD such as 
learning and memory deficits, reduced sociability, and changes in anxiety-related phenotypes 
(Allan et al., 2008; Zhao et al., 2003). Furthermore, MBD3 and multiple components of the MBD-
associated co-repressor complexes, such as NuRD, Sin3A, and NCoR/SMRT, also have critical 
roles in the brain (Knock et al., 2015; McQuown et al., 2011; Potts et al., 2011; Schoch and Abel, 
2014; Yamada et al., 2014). 
Given the similarities between the MBD proteins and the link between MBD proteins and 
neurodevelopmental disorders, we hypothesized that MBD2 may also have a role in brain 
function. Although a nurturing deficit has been reported in Mbd2 null (Mbd2-/-) mice (Hendrich et 
al., 2001), the extent to which loss of MBD2 leads to other behavioral phenotypes related to brain 
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function has yet to be determined. We carried out behavioral characterization of Mbd2-/- mice 
similar to studies of Mecp2 and Mbd1 null mice (Allan et al., 2008; Goffin et al., 2012). Many of 
the phenotypes we found in Mbd2-/- mice are seen in mice with genetic or pharmacological 
disruption to striatal dopamine (Palmiter, 2008). In order to determine if these systems are 
affected by loss of MBD2, we asked if loss of MBD2 affects biogenic amine levels or gene 
expression in the striatum. We also assessed hypothalamic neuropeptide expression to 
investigate if the low body weight observed in Mbd2-/- mice has neurological etiologies. We found 
that Mbd2-/- mice are equivalent to wildtype and heterozygous littermates on most measures, 
including behavioral assays, differentially expressed genes, and levels of biogenic amines. 
Therefore, our results indicate that MBD2, unlike the closely related proteins MeCP2 and MBD1, 
is largely dispensable for brain functions and behaviors examined in this study. 
 
METHODS 
 
Animal Husbandry 
All experiments were conducted in accordance with the ethical guidelines of the US National 
Institutes of Health and with the approval of the Institutional Animal Care and Use Committee of 
the University of Pennsylvania. All mice were housed in a standard 12 h light/12 h dark cycle with 
access to ample amounts of food and water. All experiments were performed on mice on a 
congenic sv129:C57BL/6J background unless otherwise stated. All assays were performed on 
male littermates aged 2-3 months. Mice deficient in MBD2 (Mbd2-/-) are previously described 
(Hendrich et al., 2001). All Mbd2-/- mice, wildtype and heterozygous littermates were bred from 
heterozygous parents to avoid any confounding effects from nurturing deficits reported in Mbd2-/- 
dams (Hendrich et al., 2001). Male and female mice were weighed weekly beginning at postnatal 
day 14. Mice deficient in MBD1 (Mbd1-/-) are previously described (Zhao et al., 2003). Mice were 
genotyped using a PCR-based strategy to detect mutant and wildtype alleles of Mbd2 and Mbd1. 
The genotyping primer sequences are listed in Table 2.1. 
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Table 2.1. Mbd2 and Mbd1 null mice genotyping primer sequences. 
 
Behavioral Assays  
All animal behavioral studies and video analysis were performed blinded to genotype. Mice were 
allowed to habituate to the testing room for a minimum of 30 minutes before testing began for all 
assays. Each test was performed at the same time of day. All equipment was thoroughly cleaned 
between trials. Tests were performed in the following order with less stressful assays performed 
first: zero maze, social approach, locomotor, Barnes maze, accelerating rotarod, fear 
conditioning.  
 
Locomotor 
 Locomotor activity was measured by the number of infrared beam breaks in a photobeam frame 
(Med Associates). Mice were individually placed into a home cage-like environment with clean 
bedding surrounded by the infrared photobeam frame. Activity was quantified as the total number 
of beam breaks over one sixty-minute trial. 
 
Accelerating Rotarod 
Mice were place on an accelerating rotarod apparatus (Med Associates) for 16 trials (4 trials a 
day for 4 consecutive days). Each trial lasted a maximum of 5 minutes while the rod accelerated 
from 4 to 40 rpm. Mice were allowed to rest for at least 15 minutes between trials. The time and 
Primers Sequences Product size 
 
Mbd2 knockout allele 
genotyping 
5’-ACGCTGGCCTAGTGCCGTGC-3’ 
5’-TTGTGGTTGTGCTCAGTTC-3’ 
5’-TCCGCAAACTTCTATTTCTG-3’ 
 
Wildtype: 631bp 
Mbd2 knockout: 200bp 
 
Mbd1 knockout allele 
genotyping 
 
5’-TCTTCTCAGACTGAGAAGGGTGA-3’ 
5’-CACTGAACATTGCCCAGAGCACA-3’ 
5’-AAACGGCGGATTGACCGTAATGG-3’ 
 
Wildtype: 300bp 
Mbd2 knockout: 500bp 
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rpm at which the mouse fell off the apparatus or completed a full rotation while gripping the rod 
was recorded. 
 
Zero Maze 
The elevated Zero Maze (Stoelting) consists of a circular platform with two open quadrants and 
two walled (closed) quadrants. Mice were placed in the center of one closed quadrant and 
allowed to freely explore for 5 minutes. Video recordings of each trial were hand-scored for time 
spent in open and closed quadrants. 
 
Social Approach Test 
The social approach test was performed in a three-chambered apparatus as previously described 
(Fairless et al., 2011). Mice were tested in a box with walls partially dividing the chamber into 
three areas: center, left and right. Two identical clear Plexiglas cylinders with holes were placed 
in the left and right sides. During the first habituation phase, the test mouse was placed into the 
center of the box and allowed to freely explore the three chambers with empty cylinders for 10 
minutes. During the second social test phase, an unfamiliar stimulus mouse (adult male 
gonadectomized A/J mouse; The Jackson Laboratory) was placed into one cylinder in the 
designated social chamber. A novel plastic object (paperweight) was simultaneously placed into 
the other cylinder in the designated non-social chamber. The test mouse was then allowed to 
explore freely for 10 minutes. Left and right chambers were designated as social or non-social 
chambers alternately for each trial before the trial began. Video recordings of each trial were 
analyzed with TopScan software (Clever Systems) for the time the mouse spent in each chamber 
and the time spent directly sniffing the cylinders during each test phase. 
 
Olfaction 
Mice were tested for their ability to distinguish between neutral and social odors using a 
previously described protocol with modification (Yang and Crawley, 2009). Mice were placed 
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individually into a clean cage with bedding and presented with cotton-tipped wooden applicators 
dipped in water, almond extract, or bedding of an unfamiliar cage. Each stimulus scent was 
presented for 1 minute with a 1-minute inter-trial interval. Time spent sniffing was defined as time 
the animal spent oriented with its nose 2 cm or closer to the cotton tip with scent. 
 
Buried food retrieval 
Mice were tested for their ability to find a small piece of hidden food using a previously described 
protocol with modifications (Yang and Crawley, 2009). For two consecutive days before testing, 
single-housed mice were presented with a piece of novel palatable food (one piece of sweetened 
cereal). Mice that did not consume the cereal by the next day were excluded from the study. To 
test the mice, a piece of cereal was buried under clean bedding in a new cage in a randomly 
determined corner. Mice were placed in the new cage and the amount of time needed to find and 
begin eating the buried food was recorded. 
 
Nesting 
Nesting behavior was assessed using the scoring system previously described (Deacon, 2006). 
Mice were single housed with clean bedding and provided with a pressed square of cotton. 
Twenty-four hours later, nests were assigned a score of 0 (no nest building behavior observed) to 
5 (cup shaped nest with high walls, all material used).  
 
Barnes Maze 
Mice were tested for spatial learning and memory using a Barnes maze (Sunyer et al., 2007) 
(San Diego Instruments), which consists of a white circular platform (36 inch diameter) with 20 
holes (2 inch diameter) around the perimeter. An escape box was located under the target hole. 
Entry into off-target holes was blocked by a piece of black Plexiglas. The platform was 36 inches 
above the floor and four distinct visual cues were placed on the walls surrounding the platform. 
During each trial, the test mouse was allowed to explore the maze until the mouse found and 
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entered the escape box or for a maximum of 150 seconds. If the mouse did not enter the escape 
box at the completion of the trial, it was gently guided into the box by the experimenter and 
allowed to remain there for 1 minute before returning to its home cage. Mice were trained in one 
trial per day for four consecutive days. Trials were video recorded and analyzed with TopScan 
software (Clever Systems). Measures quantified included primary latency (time to initially reach 
the target hole) and total latency (time to enter escape box through target hole), and number of 
errors (visits to non-target holes). 
 
Fear conditioning 
On the training day, mice were placed in individual chambers (Med Associates) for two minutes 
followed by a loud tone (85 dB, 2 kHz) for 20 seconds, co-terminating with a two second, 0.75-mA 
foot shock. Mice were left undisturbed for two minutes, after which a second tone-shock pairing 
was delivered. Mice were returned to their home cage 90 seconds after the second shock. 
Twenty-four hours later, mice were tested for context-dependent memory by being placed into the 
same testing chambers without a tone or shock for 5 minutes. One hour later, mice were tested 
for cued memory by being placed into a novel chamber for two minutes and playing the same 
loud tone without shock for one minute. Freezing behavior, defined as no movement except for 
respiration, was analyzed with FreezeScan NI version 2.0.  
 
Food Intake 
Single-housed male mice were each given 150g of standard chow in their home cages. Mice had 
unrestricted access to food and water during testing. For two consecutive days, food was 
removed, weighed, and carefully replaced to habituate mice to this process. Measurements from 
the first two days were not included in the analysis. Food was removed, weighed, and replaced 
for five consecutive days following habituation and mice were weighed on the final testing day.  
 
Quantitative reverse transcription PCR 
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Total RNA was isolated using Trizol reagent (Invitrogen) and treated with TURBO DNase 
(Ambion). cDNA was generated from 1 µg of total RNA by random hexamer priming using 
SuperScriptIII reverse transcriptase (Invitrogen). Quantitative PCR (qPCR) was performed on 10 
ng of the resulting cDNA using SYBR Green detection (Applied Biosystems). All qPCR primer 
pairs are exon-spanning and listed in Table 2.2. Gapdh was used as an internal normalization 
control. 
 
Table 2.2. Primers used for RT-qPCR. 
 
HPLC analysis of monoamine levels 
Brain tissues were resected on ice, weighed, and immediately frozen in liquid nitrogen. Samples 
were sonicated on ice for 10 sec in homogenizing buffer containing 250nM 3,4-
dihydroxybenzylamine as an internal standard, followed by centrifugation at 14,000 rpm at 0°C for 
20 min. Levels of monoamines were determined using HPLC with standard methods as described 
previously (Howerton et al., 2014). The standard curve was from 0-10 pmol for each monoamine. 
Data acquisition and analysis was performed by blinded to genotype. 
 
RNA-seq 
Total RNA was isolated using Trizol reagent (Invitrogen) and treated with TURBO DNase 
(Ambion). 2µg of total RNA was used as input with the TruSeq Stranded mRNA Library Prep Kit 
(Illumina) according to the manufacturer’s instructions. Samples were sequenced to an 
Gene Forward Primer Reverse Primer 
Agrp 5’-TAGATCCACAGAACCGCGAGT-3’ 5’-GAAGCGGCAGTAGCACGTA-3’ 
Npy 5’-CTCCGCTCTGCGACACTAC-3’ 5’-AGGGTCTTCAAGCCTTGTTCT-3’ 
Pomc 5’-CTGGAGACGCCCGTGTTTC-3’ 5’-TGGACTCGGCTCTGGACTG-3’ 
Mbd2 5’- AACTGGAGGAGGCACTGATG-3’ 5’- GGGGAAGGTCAGTCGAAAGT-3’ 
Mecp2 5’-CATACATAGGTCCCCGGTCA-3’ 5’-CAGGCAAAGCAGAAACATCA-3’ 
Gapdh 5’-GATGCCCCCATGTTTGTGAT-3’ 5’-GGTCATGAGCCCTTCCACAAT-3’ 
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approximate depth of 50 million reads per sample at 100 nucleotides using the HiSeq 2000 
(Illumina). The raw FASTQ files of the RNA-seq were mapped using STAR program (Dobin et al., 
2013) under the parameters of "--outFilterMultimapNmax 1 --outFilterMismatchNmax 3". Number 
of reads for each gene was counted using in house Perl programs. Differentially expressed genes 
were identified by edgeR (Robinson et al., 2010) with a false discovery rate (FDR) < 0.05. 
 
Statistics 
Statistical analysis was performed using Prism 6.0 (GraphPad Software). Individual statistical 
tests are stated in the figure legends. 
 
RESULTS 
 
Behavioral characterization of Mbd2 null mice 
Given that genetic studies of humans and mice have linked several MBD proteins to ASD 
and neurodevelopmental disorders, we hypothesized that MBD2 may also have a critical role in 
brain function and that loss of MBD2 would result in behavioral phenotypes similar to those 
observed in Mecp2 or Mbd1 null mice (Allan et al., 2008; Camarena et al., 2014, 5; Du et al., 
2015; Guy et al., 2001). Although an Mbd2 null mouse (Mbd2-/-) has been generated, the only 
reported phenotype is a pup nurturing and retrieval deficit (Hendrich et al., 2001) and a full 
phenotypic characterization has not been reported. In this mouse, exon 2 of Mbd2 is replaced 
with a promoterless 7kb β-Geo LacZ cassette, removing most of the conserved MBD (Hendrich et 
al., 2001). Small amounts of read-through transcript are present, but no full-length protein of 
either MBD2 isoform (MBD2a and MBD2b) is detectable, indicating this is a null allele (Hendrich 
et al., 2001). We focused our analysis on behavioral phenotypes that are affected in mouse 
models of ASDs, such as Mecp2 or Mbd1 null mice, and assessed motor function, anxiety-related 
behaviors, sociability, and learning and memory (Allan et al., 2008; Goffin et al., 2012; Pasciuto et 
al., 2015).  
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Changes in locomotor activity have been observed in Mecp2 null mice (Goffin et al., 
2012) so we quantified the locomotor activity of Mbd2-/- mice in a home-cage like environment. 
We found that Mbd2-/- mice show significantly reduced locomotor activity compared to wildtype 
(Mbd2+/+) and heterozygous (Mbd2+/-) littermates (Figure 2.1.A). We then asked if the observed 
hypoactivity could be attributed to motor impairments, as motor function is also affected in Mecp2 
null mice (Goffin et al., 2012). We tested motor coordination and learning in a rotarod task, in 
which mice were challenged to stay on an accelerating rod for 16 total trials over four days. All 
genotypes showed comparable improvement in this task over each trial and testing day, 
indicating that motor coordination and learning is not impaired in Mbd2-/- mice (Figure 2.1.B). 
Anxiety-related phenotypes are altered in both Mecp2 and Mbd1 null mice (Allan et al., 2008; 
Goffin et al., 2012). Therefore, we used a zero maze to assess anxiety, a task that takes 
advantage of a mouse’s innate preference for enclosed spaces. Mice that spend increased time 
in the open arm of the maze are inferred to have decreased anxiety-related behavior (Crawley, 
2007). We found Mbd2-/- mice displayed a preference for the closed arm that was equivalent to 
control littermates, indicating that anxiety-related behavior is not affected by the loss of MBD2 
(Figure 2.1.C). 
 We next assessed whether Mbd2-/- mice exhibited several autistic-like phenotypes that 
have been shown to be affected in mice lacking MeCP2 or MBD1 (Allan et al., 2008; Goffin et al., 
2012). Impaired social interaction is a common feature of ASDs and is recapitulated in numerous 
mouse models (Fairless et al., 2011; Pasciuto et al., 2015). Mice are inherently social animals 
and most mice prefer to interact with other mice (Fairless et al., 2011). We tested sociability of 
Mbd2-/- mice using the social approach test in a three-chambered apparatus (Figure 2.1.D). This 
assay tests the preference of the test mouse to interact with a novel social stimulus (unfamiliar 
mouse) or novel object. In the first habituation phase of the test, Mbd2+/+, Mbd2+/- and Mbd2-/- 
mice showed no significant difference in time spent sniffing two empty cylinders. At the start of 
the second phase of the test, a novel stimulus mouse and novel object were introduced to the 
cylinders. We found no significant difference between Mbd2+/+, Mbd2+/-, and Mbd2-/- littermates in 
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the amount of time spent sniffing the social stimulus mouse, suggesting sociability is not affected 
by the loss of MBD2.  
Detection of olfactory cues is essential for many murine behaviors including social 
interactions. MBD2 and MeCP2 deficient mice have impairments in differentiation or proliferation 
of olfactory receptor neurons, but it is unknown if olfaction is affected (Macdonald et al., 2010). 
Impairment in olfactory ability may affect outcomes in the sociability assay and other behavior 
tests. Therefore, we evaluated olfaction by testing whether Mbd2-/- mice can distinguish between 
scent cues in a swab-sniff test (Figure 2.1.E). We found that all genotypes spent more time 
sniffing a social scent versus neutral water or almond scents as expected, indicating these mice 
have the olfactory ability to distinguish between scents. However, Mbd2-/- mice spent significantly 
less time sniffing a social scent than wildtype littermates. This result may be due to decreased 
home-cage activity (Figure 2.1.A) because there is a trend for Mbd2-/- mice to spend less time 
sniffing the neutral scent swabs as well. Alternatively, this result may indicate olfactory 
impairment. To distinguish between these possibilities, we performed a secondary olfaction test in 
which we quantified the time needed for mice to find and retrieve a buried piece of food in a clean 
home cage (Figure 2.1.F). Mbd2-/- mice found and retrieved the hidden food as quickly as 
littermates, indicating these mice can detect and respond to olfactory cues similarly to littermates. 
We next assayed nest building as test that is commonly used to assess home cage 
behaviors. Nesting is a spontaneous, complex behavior and is considered to be an indicator of 
home-cage social behavior and general welfare in mice (Deacon, 2006). Nesting is affected by 
neurological and as well as external factors affecting behavior. Several mouse models of ASD 
and neurodegenerative disease and mice experiencing social defeat have impaired nesting 
activity (Jirkof, 2014; Otabi et al., 2015; Pasciuto et al., 2015). We found that Mbd2-/- mice show 
impaired nest building activity in contrast to wildtype and heterozygous littermates (Figure 2.1.G). 
Together with the reduced home-cage locomotor activity (Figure 2.1.A), these findings indicate 
that Mbd2-/- mice have altered home-cage behaviors but the exact etiologies of these changes in 
behavior are difficult to determine. 
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 Deficits in learning and memory have been found in numerous mouse models of ASDs 
and have also been observed in mice lacking MeCP2 or MBD1 (Allan et al., 2008; Goffin et al., 
2012; Pasciuto et al., 2015). To determine if Mbd2-/- mice have a similar phenotype, we tested 
spatial learning and memory using the Barnes maze paradigm over four consecutive training 
days. Mbd2-/- mice showed a slight but significant increase in the time needed to initially reach the 
target hole on the second training day (primary latency, Figure 2.1.H), but equal time to enter the 
target hole and complete the trial on all testing days (total latency, Figure 2.1.I) compared to 
wildtype and heterozygous littermates. The increase in primary latency time on the second 
training day is unlikely to reflect significant changes in learning and memory because Mbd2-/- 
mice are comparable to control littermates on all other measures in this assay, including the 
number of errors made on all days (total number of visits to non-target holes, Figure 2.1.J).  
 As the Barnes maze paradigm primarily tests hippocampal-dependent spatial memory, 
we also sought to determine if other aspects of learning and memory are affected in Mbd2-/- mice. 
The fear conditioning test assesses amygdala-dependent cued memory in addition to amygdala- 
and hippocampus-dependent contextual memory (Crawley, 2007). During training, there were no 
significant differences between genotypes in freezing behavior before or after the foot shock 
(Figure 2.1.K). On the testing day, Mbd2-/- mice showed significantly less cue-dependent freezing 
behavior than wildtype and heterozygous littermates, but equivalent context-dependent freezing 
behavior. Although these findings may be indicative of a mild learning and memory phenotype, 
the altered home-cage activity levels (Figure 2.1.A) may confound the results obtained here. 
Furthermore, the absence of a significant phenotype in the Barnes maze analysis (Figure 2.1.H-J) 
support that these findings may be attributed to differences in activity rather than learning and 
memory phenotypes.  
In summary, we found that Mbd2-/- mice are equivalent to wildtype and heterozygous 
littermates on most measures tested, with the notable exception of homecage locomotor activity 
and nest building. These results are in contrast to mice lacking MeCP2 or MBD1, which show 
significant alterations in locomotor activity, sociability, anxiety-related behaviors and deficits in 
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learning and memory (Allan et al., 2008; Goffin et al., 2012). Therefore we conclude that unlike 
most MBD proteins, MBD2 does not have a major impact on brain functions that underlie many 
key behavioral phenotypes relevant to ASD. 
 
Mbd2-/- mice have reduced body weight and decreased food intake associated with altered 
hypothalamic neuropeptide expression 
 Although Mbd2-/- mice are viable and fertile as previously reported (Hendrich et al., 2001), 
we noticed that these mice have reduced reproductive ability. We also weighed Mbd2+/+, Mbd2+/-, 
and Mbd2-/- male and female littermates and found that Mbd2-/- males and females have subtle 
but significantly lower body weights beginning at 4 and 6 weeks of age, respectively (Figure 
2.2.A,B). Loss of MeCP2 and MBD1 both affect brain weight, as well (Goffin et al., 2012; Zhao et 
al., 2003). Therefore, we tested if brain weight is affected in Mbd2-/- mice and compared these 
values to total body weight. We observed that Mbd2-/- male mice have slightly but significantly 
decreased brain weight, but have increased brain weight as a percentage of body weight 
compared to littermates (Figure 2.2.C,D). This finding suggests that the low brain weight of Mbd2-
/- mice is likely due to loss of overall body mass. 
To further explore the low body weight observed in Mbd2-/- mice, we next measured daily 
food intake for each genotype. We found that male Mbd2-/- mice consume less food per day 
compared to wildtype and heterozygous littermates (Figure 2.2.E). However, when food 
consumption is normalized to body weight, Mbd2-/- mice consume comparable amounts of food 
for their body size as littermates (Figure 2.2.F). These findings are in contrast to mice with Mecp2 
mutations, which show increasing phenotypic severity with age in addition to significantly reduced 
body and brain weight (Goffin et al., 2012).  
We then asked if the low body weight observed in Mbd2-/- mice has a neuronal origin. 
Neuronal systems sense levels of circulating hormones such as leptin and insulin and nutrient 
signals in order to regulate body energy stores and feeding activity (Schwartz, 2005). The arcuate 
nucleus of the hypothalamus contains several populations of neurons including the orexigenic 
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agouti-related peptide (AgRP)–neuropeptide Y (NPY) neurons that stimulate food intake and 
reduce energy expenditure and the anorxegenic proopiomelanocortin (POMC) neurons that 
reduce appetite and stimulate energy expenditure. Lower levels of body fat and caloric intake are 
associated with reduced levels of leptin, which in turn increases expression of Agrp and Npy and 
downregulates expression of Pomc (Yi and Tschop, 2012) (Figure 2.3.A). Changes in expression 
of these peptides are therefore indicative of hypothalamic sensing of an energy imbalance. 
However, this does not reveal the etiology of the imbalance, which may be affected by neuronal 
factors such as reduced dopamine signaling (Yang et al., 2014a) or extrinsic factors such as a 
high fat diet (Schwartz, 2005). 
We examined the expression levels of the orexigenic peptides Agrp and Npy and 
anorexigenic peptide Pomc and in the hypothalamus of three-month old wildtype and Mbd2-/- mice 
using RT-qPCR (Figure 2.3.B). As a control, we also determined that Mbd2 expression is 
significantly reduced and Mecp2 expression is unchanged in Mbd2-/- mice, as expected. In Mbd2-
/- mice, Pomc is significantly downregulated, which indicates hypothalamic sensing of a energy or 
nutrient deficit. Unexpectedly, Agrp and Npy expression show no statistically significant 
differences between wildtype and Mbd2-/- mice and in fact show a trend towards down regulation. 
Together, these results signify that Mbd2-/- mice are sensing a nutrient deficit but are not 
motivated neurochemically to increase their food consumption. 
 
Mbd2-/- mice have equivalent biogenic amine content and few differentially expressed 
genes in the striatum compared to wildtype littermates 
Although Mbd2-/- mice are comparable to control littermates on most measures, we next 
sought to determine if the observed changes in locomotor activity, body weight, and impaired 
nesting behavior are linked to any alterations in biogenic amine levels. Genetic or 
pharmacological disruption of biogenic amine levels, particularly striatal dopamine, is associated 
with many of these phenotypes, including low body weight, hypophagia, hypoactivity, and 
impairments in nesting and pup nurturing (Henschen et al., 2013; Palmiter, 2008; Yang et al., 
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2014a). We performed HPLC analysis to measure the abundance of essential monoamines and 
their metabolites in the cortex and striatum of wildtype and Mbd2-/- littermates (Figure 2.4.A,B). 
These include norepinephrine (NE), dopamine (DA) and its metabolites 3,4-
dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA), serotonin (5-HT) and its 
metabolite 5-hydroxyindoleacetic acid (5-HIAA). We found that none of the measured biogenic 
amine levels in the cortex and striatum are altered in Mbd2-/- mice compared to wildtype 
littermates. Therefore, the loss of MBD2 is unlikely to affect monoamine signaling in the brain, in 
contrast to the essential role of MeCP2 in regulating these systems (Panayotis et al., 2011). 
In addition to examining biogenic amines particularly in the striatum, we also sought to 
determine if loss of MBD2 is associated with significant changes in gene expression in the brain. 
We assessed differentially expressed genes (DEGs) in the striatum of adult wildtype and Mbd2-/- 
littermates, as disruption to striatal signaling and particularly dopamine is associated with many of 
the phenotypes observed in Mbd2-/- mice (Henschen et al., 2013; Palmiter, 2008; Yang et al., 
2014a). We performed poly-A selected mRNA-seq and first analyzed the total number of reads 
and mapped reads (Table 2.3). As an additional experimental verification, we determined that 
there are no reads mapped to exon 2 of Mbd2 in Mbd2-/- mice, as this exon is deleted (Hendrich 
et al., 2001) (Figure 2.5).  
We found a total of 38 DEGs using an FDR value of <0.05, including 21 genes 
upregulated and 17, including Mbd2, downregulated. Of these DEGs, 18 genes showed greater 
than 2-fold change in expression comparing wildtype to Mbd2-/- mice (Figure 2.6). The DEGs 
have diverse functions with no significant enrichment for any gene ontology terms (data not 
shown, Figure 2.7). Although several genes have been linked to ASDs, it is not clear if MBD2 is 
directly regulating expression of these genes or if the DEGs are secondary effects of MBD2 
function in other cell types or systems. In either scenario, further work is required to determine the 
biological implications of altered expression of these genes and whether they contribute to the 
phenotypes observed in Mbd2-/- mice. 
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Table 2.3. Total and uniquely mapped reads from wildtype and Mbd2-/- poly-A selected 
RNA-seq in the striatum. 
 
DISCUSSION 
 
 In this study, we show that loss of MBD2, relative to MeCP2 and MBD1, surprisingly has 
only a minor impact on brain function. We present the first behavioral characterization of Mbd2-/- 
mice, with emphasis on phenotypes affected by loss of related proteins MeCP2 or MBD1 (Allan et 
al., 2008; Goffin et al., 2012). In addition to behavior, we also assessed whether loss of MBD2 
affects hypothalamic and striatal gene expression and biogenic amine levels in the striatum. 
Unexpectedly, we found that loss of MBD2 results in few subtle behavioral phenotypes. 
Most behavioral measures were generally unaffected in Mbd2-/- mice compared to wildtype and 
heterozygous littermates, including motor coordination and learning, anxiety-related behaviors, 
sociability, olfaction, and spatial and contextual learning and memory (Figure 2.1). In contrast, 
mice with loss of MeCP2 or MBD1 show significant deficits on the majority of these measures 
(Allan et al., 2008; Goffin et al., 2012). We found that Mbd2-/- mice are hypoactive in a home-cage 
environment (Figure 2.1.A) and show significant differences to littermates in measures of nest 
building and olfaction (Figure 2.1.E,G). Specifically, we observed that Mbd2-/- mice spend 
significantly less time engaged in sniffing behavior of a social scent during a test of olfactory 
discrimination (Figure 2.1.E). Finally, Mbd2-/- mice show reduced cue-dependent freezing 
behavior in a fear conditioning assay (Figure 2.1.K). 
Despite finding statistically significant differences between Mbd2-/- mice and control 
littermates on several tests, the results of all tests as a whole must be considered before 
Sample Total Reads Uniquely Mapped Reads 
Wildtype Replicate 1 57,648,692 49,232,956 (85.40%) 
Wildtype Replicate 2 51,110,555 43,509,724 (85.13%) 
Mbd2-/- Replicate 1 66,516,889 56,179,825 (84.46%) 
Mbd2-/- Replicate 2 44,545,090 37,886,828 (85.05%) 
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interpreting results of individual tests as discrete behavioral phenotypes. Most importantly, the 
hypoactivity phenotype (Figure 2.1.A) complicates the interpretation of several tests that depend 
on activity levels, in particular nesting, the swab sniff olfaction test, and fear conditioning. 
Phenotypes such as hypoactivity, nesting, and low body weight are multigenic and complex in 
nature and therefore it is challenging to determine the precise etiologies of these phenotypes 
(Gaskill et al., 2013; Reed et al., 2008; Tou and Wade, 2002). Furthermore, low body weight 
(Figure 2.2.A,B) is inexorably linked to activity levels, and therefore must also be considered in 
interpretation of these phenotypes (Tou and Wade, 2002).  
Changes in body weight have been observed in over 30% of viable, single-gene null 
mice, which illustrates the sensitivity of this phenotype to genetic perturbations in multiple cellular 
processes (Reed et al., 2008). While hypoactivity has been observed in several mouse models of 
ASD including Mecp2 null mice, in these mice hypoactivity is accompanied by significant deficits 
in other behavioral measures such as learning and memory deficits or seizures, supporting a 
neuronal etiology (Goffin et al., 2012; Pasciuto et al., 2015). The origins of changes in nesting 
behavior are similarly challenging to classify in this scenario. Nesting can be affected by a range 
of experimental factors, such as genetic models of neurodegenerative disease, pharmacological 
treatments, or external factors such as stress arising from social defeat (Jirkof, 2014; Otabi et al., 
2015; Pasciuto et al., 2015). Therefore, we conclude that the nesting deficits observed in Mbd2-/- 
mice are likely related to the overall reduced home cage activity levels (Figure 2.1.A), but we 
cannot precisely determine the cause of impaired nesting in Mbd2-/- mice without further 
additional experiments. 
We found that Mbd2-/- mice spend significantly less time sniffing a social scent during a 
test of olfaction than control littermates (Figure 2.1.E). However, we expect that this finding does 
not indicate that olfactory ability is impaired in Mbd2-/- mice to the extent that it would affect 
behaviors for the following reasons. First, Mbd2-/- mice show a trend of spending less time sniffing 
overall during the water and almond phases of this test, indicating that the decreased sniffing of 
the social scent may be more indicative of lower overall home cage activity levels (Figure 2.1.A) 
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rather than a true olfactory deficit. This conjecture is supported by our findings that there is no 
significant difference between genotypes in time spent sniffing a cylinder containing a novel 
stimulus animal in a sociability assay (Figure 2.1.D) or the buried food retrieval assay, an 
independent olfaction test (Figure 2.1.F).  
Similarly, we found subtle changes between Mbd2-/- mice and control littermates in the 
Barnes maze assay and cued fear conditioning (Figure 2.1.H-K), but we hypothesize that these 
results may be linked to reduced overall activity levels rather than representing specific deficits in 
learning and memory. In the Barnes maze assay, if spatial memory were directly affected in 
Mbd2-/- mice, we would expect to see increased primary and total latency on additional training 
days (Figure 2.1.H,I) or increased errors (Figure 2.1.J). However, Mbd2-/- mice are equivalent to 
control littermates on all measures with the exception of primary latency on the second training 
day (Figure 2.1.H), indicating that spatial memory is likely unaffected. In a fear-conditioning 
assay, we found that Mbd2-/- mice show significantly more time freezing in response to cue, but 
not a context, associated with an aversive foot shock (Figure 2.1.K). The results on this assay are 
difficult to interpret because Mbd2-/- mice show a trend of reduced freezing behavior during the 
training phase after the foot shock, although this difference is not statistically significant. The 
readout for this assay, freezing behavior, is also activity-dependent and the overall decreased 
activity levels in Mbd2-/- mice may confound the results. Therefore, this assay must be repeated to 
ensure that Mbd2-/- mice have an equivalent pain threshold and freezing response to control 
littermates. 
In summary, Mbd2-/- mice show subtle phenotypes on several measures but several of 
these results may be indicative of overall reduced activity levels rather than additional, specific 
phenotypes related to brain function. The phenotypes that are clearly affected, including home-
cage activity, nesting and body weight, are complex and multigenic in nature and may have non-
neuronal etiologies. Therefore, in the absence of additional changes in behavior, striatal gene 
expression changes, or biogenic amine levels, we expect that the observed subtle behavioral 
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phenotypes are likely not neuronal in origin. We conclude that, unlike most MBD proteins, MBD2 
is largely not required for brain functions that affect behavioral outcomes examined here. 
We also found that loss of MBD2 results in subtle, but significantly decreased body 
weight (Figure 2.2A,B). Although Mbd2-/- mice eat less food per day, they consume equivalent 
food normalized to body weight as wildtype littermates (Figure 2.2.E,F). These findings support 
the conclusion that low body weight is established early in Mbd2-/- mice after weaning, after which 
Mbd2-/- mice stabilize and continue to eat a sufficient amount of calories to maintain their body 
weight at steady state (Figure 2.2.A,B). Although Mbd2-/- mice maintain their body weights, they 
do show altered expression levels of the hypothalamic peptide Pomc (Figure 2.3.B). Reduced 
Pomc expression is generally caused by reduced levels of serum leptin associated with reduced 
adipose tissue. Downregulation of Pomc expression is usually accompanied by increased 
expression of the orexigenic peptides Npy and Agrp, which together stimulate increased food 
intake and reduced energy expenditure (Myers et al., 2008). Paradoxically, Mbd2-/- mice show a 
trend, although not statistically significant, for downregulation of hypothalamic Agrp and Npy 
(Figure 2.3.B). This finding may indicate that loss of MBD2 is directly affecting hypothalamic gene 
expression. Alternatively, energy homeostasis pathways may be affected in Mbd2-/- mice at one 
or multiple different areas, including the liver or levels of circulating hormones, for example. Due 
to the absence of significant behavioral phenotypes, striatal gene expression changes, or 
biogenic amine levels in Mbd2-/- mice, we hypothesize that the reduced Pomc expression is likely 
due to changes in peripheral tissues and pathways and does not reflect a specific hypothalamic 
function for MBD2. 
To determine if loss of MBD2 affects brain function at the molecular or cellular level, we 
assessed biogenic amine levels in the striatum and cortex and also looked for gene expression 
changes in the striatum. We choose to examine the striatum because genetic or pharmacological 
disruptions to this system, and particularly striatal dopamine signaling, produce phenotypes 
similar to those seen in Mbd2-/- mice, including hypoactivity, low body weight, hypophagia, and 
altered nurturing behavior (Bromberg-Martin et al., 2010; Henschen et al., 2013; Palmiter, 2008). 
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We did not find any significant alterations in the levels of biogenic amines and their metabolites in 
the striatum or cortex of Mbd2-/- mice, unlike what has been observed in Mecp2 or Mbd1 null mice 
(Figure 2.4.A,B) (Allan et al., 2008; Panayotis et al., 2011). These results indicate that the 
phenotypes of Mbd2-/- mice are likely not related to changes in biogenic amine signaling pathways 
such as striatal dopamine, and instead may have more complex or non-neuronal origins. 
In addition to assessing levels of biogenic amines in the striatum, we also sought to 
determine if gene expression is altered in the striatum upon loss of MBD2. The striatal DEGs in 
Mbd2-/- mice have diverse functions (Figure 2.7). Several of the DEGs have been linked to brain-
specific functions related to ASD. Mutations in Grin2b, an NMDA receptor subunit, are associated 
with intellectual disability, ASD and seizures (Endele et al., 2010). Engrailed homeobox factor 2 
(En2) is upregulated during CNS development and is also linked to neurological phenotypes in 
mouse models and human patients (Benayed et al., 2005; Cheh et al., 2006). Several DEGs point 
to increased inflammatory stress in Mbd2-/- mice. For example, lipocalin2 (Lcn2) is upregulated in 
the prefrontal cortex and hippocampus in response to stress or neural injury such as stroke and 
elevated transthyretin (Ttr), the primary transporter of thyroid hormone and retinol in the cerebral 
spinal fluid, is used clinically as a marker of inflammatory stress (Buxbaum and Reixach, 2009; 
Lee et al., 2009). While these findings indicate directions for future investigations, it is unclear if 
expression levels of the DEGs are directly affected by MBD2-mediated transcriptional 
mechanisms or if these are secondary effects of loss of MBD2 in other cell types or systems. Due 
to the absence of notable behavioral phenotypes and unchanged biogenic amine levels in the 
striatum of Mbd2-/- mice, the DEGs observed are likely to be secondary effects of loss of MBD2 
rather than an indication of brain-specific MBD2 functions.  
 Although these phenotypes of Mbd2-/- mice are complex, additional experiments would 
clarify these findings. First, despite the absence of robust behavioral phenotypes, a subtler 
neuronal cellular phenotype may be present in Mbd2-/- mice. One study found that olfactory 
receptor neurons in Mbd2-/- mice show enhanced proliferation but reduced lifespan and 
differentiation capability (Macdonald et al., 2010). However, it is unclear how or if this cellular 
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phenotype may affect olfactory function as we did not detect a notable difference in odor-induced 
behaviors in these mice on several independent tests (Figure 2.1.D-F). It is therefore possible 
that additional cellular phenotypes may be present without significantly affecting the behaviors 
examined in this study in adult mice. 
 Because Mbd2-/- mice have significantly decreased home-cage activity and reduced body 
weight (Figure 2.1.A, Figure 2.2.A,B), these phenotypes may confound the interpretation of 
several other behavior tests performed in this study that rely on mobility and activity. Therefore, to 
better understand the phenotype of Mbd2-/- mice it would be beneficial to perform additional tests 
that do not directly or indirectly measure activity levels as an output. For example, prepulse 
inhibition can be used to assess deficits in sensorimotor gating and is affected by loss of MBD1 in 
mice (Allan et al., 2008). Alternatively, the Y-maze spontaneous alteration test assesses spatial 
cognition but does not depend on the subject mouse’s speed to reach a target, as does the 
Barnes maze (Crawley, 2007). 
 Another approach to study the effects of loss of MBD2 would be to perform the tests 
described here on mice with conditional loss or rescue of MBD2. It is likely that several of the 
phenotypes of Mbd2-/- mice such as low body weight and hypoactivity are interrelated and may 
even have a synergistic effect. By genetically isolating MBD2 functions to a specific cell type or 
tissue, it may be possible to determine which phenotypes are direct consequences of loss of 
MBD2 and which may be secondary effects. For example, an Mbd2 conditional null and/or rescue 
mouse would be beneficial to study the low body weight phenotype of Mbd2-/- mice. If a brain-
specific Mbd2 null mouse also had low body weight, this would be strong evidence that this 
phenotype is neuronal in origin and may be primarily attributed to misregulation in the 
hypothalamus, for example. Alternatively, this phenotype could be due to a gastrointestinal-
related MBD2 function that could be explored through an intestine epithelial cell-specific loss of 
MBD2.  
 In summary, we found that loss of MBD2 results in subtle phenotypes including low body 
weight, hypoactivity, and deficits in nesting behavior. We also determined that loss of MBD2 
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reduces expression of the anorexigenic hypothalamic peptide Pomc and affects expression of a 
limited number of genes in the striatum. However, additional experiments are required to assess 
if expression of these differentially expressed genes is directly regulated by MBD2-dependent 
mechanisms, or if these findings represent secondary effects of loss of MBD2. The limited 
number of genes affected and the equivalent levels of biogenic amines in the brain of Mbd2-/- 
mice support the hypothesis that these are likely to be indirect effects. We conclude that, in 
contrast to MeCP2 or MBD1, MBD2 is generally not required for the behavioral outcomes and 
brain functions examined in this study. 
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CHAPTER 2 FIGURES 
 
Figure 2.1. Behavioral characterization of Mbd2-/- mice compared to wildtype and 
heterozygous littermates.  
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Figure 2.1 Behavioral characterization of Mbd2-/- mice compared to wildtype and 
heterozygous littermates. 
(A) Mbd2-/- mice are hypoactive as measured by the number of infrared beam breaks in a home-
cage like environment over sixty minutes (n = 14 per genotype, **P < 0.01, *P < 0.05, one-way 
ANOVA with Tukey’s test). (B) Mbd2-/- mice perform similarly to littermates in the rotarod task 
indicating unaffected motor coordination or learning (n = 14 per genotype, two-way ANOVA). (C) 
Mbd2-/- mice have unaltered anxiety-related behavior in a zero maze assay (n = 14 per genotype, 
one-way ANOVA of time in open arm). (D) Sociability of Mbd2-/- mice was assessed in the social 
approach test in a three-chambered apparatus. All genotypes show equal preference between 
two empty cylinders (left and right) during the habituation phase. All genotypes show equivalent 
increased preference for a social stimulus (mouse) versus a non-social stimulus (object) (Mbd2+/+ 
and Mbd2+/- n = 13, Mbd2-/- n = 14, two-way ANOVA). (E) The ability to distinguish between 
neutral (water and almond) and social scents was determined by assessing time spent sniffing a 
swab with each scent. All genotypes have increased interaction (sniffing) with a social scent 
compared to neutral scents, but Mbd2-/- show significantly less time sniffing a social scent (n = 12 
per genotype, P < 0.0001 effect of scent, P < 0.001 effect of genotype, **P < 0.01, two-way 
ANOVA with Tukey’s test). (F) Mbd2-/- mice take equivalent time to littermates to find and retrieve 
a buried piece of food in a home-cage like environment (Mbd2+/+ and Mbd2-/- n = 13, Mbd2+/- n = 
11, ns not significant, one-way ANOVA). (G) Mbd2-/- mice have significantly impaired nest-
building behavior (Mbd2+/+ n = 22, Mbd2+/- n = 19, Mbd2-/- n = 18, **P < 0.01, one-way ANOVA 
with Tukey’s test). (H-J) Spatial learning and memory were assessed using a Barnes maze 
paradigm. Mbd2-/- mice show a slight but significant delay to initially reach a target escape hole on 
the second training day (primary latency, H), but equivalent time to enter the escape hole (total 
latency, I) during four days of training. Mbd2-/- mice made comparable numbers of errors to 
control littermates (visits to non-target hole, J) during all training days (Mbd2+/+ n = 22, Mbd2+/- n = 
19, Mbd2-/- n = 18, *P <0.05, two-way ANOVA with Tukey’s test). (K) In a fear conditioning 
learning and memory assay, all genotypes responded with equivalent freezing behavior to a 
paired tone-footshock. Mbd2-/- mice showed significantly less freezing behavior in response to a 
cued stimulus, but equivalent freezing behavior to a contextual stimulus compared to control 
littermates (Mbd2+/+ and Mbd2-/- n = 14, Mbd2+/- n = 12, *P <0.05, two-way ANOVA with Tukey’s 
test). All data are presented as mean ±SEM. 
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Figure 2.2. Mbd2-/- mice show decreased body and brain weight associated with reduced 
food intake. 
(A) Male Mbd2-/- mice have decreased body weight compared to Mbd2+/+ and Mbd2+/- littermates 
(n = 10 per genotype, P < 0.01, interaction, two-way ANOVA). Mbd2-/- weight was significantly 
decreased at 4 weeks continuing to 18 weeks postnatal (**P < 0.01, two-way ANOVA with 
Tukey’s test). (B) Female Mbd2-/- mice have decreased body weight (n = 10 per genotype, P < 
0.001, interaction, two-way ANOVA). Mbd2-/- weight was significantly decreased at 6 weeks 
continuing to 8 weeks postnatal (***P < 0.001, two-way ANOVA with Tukey’s test). (C) 13-week 
old male Mbd2-/- mice have significantly decreased brain weight (Mbd2+/+ and Mbd2+/- n = 11, 
Mbd2-/- n = 12, **P < 0.01, one-way ANOVA with Tukey’s test). (D) 13-week old male Mbd2-/- mice 
have significantly increased brain weight as a percentage of body weight (Mbd2+/+ and Mbd2+/- n 
= 11, Mbd2-/- n = 12, **P < 0.01, one-way ANOVA with Tukey’s test). (E) 8 week old male Mbd2-/- 
mice consume significantly less food per day on an unrestricted diet of standard chow, but (F) 
consume equivalent food normalized to body weight (Mbd2+/+ and Mbd2+/-, n = 5, Mbd2-/- n = 8, * 
P <0.05, ns not significant, one-way ANOVA with Tukey’s test). All data are presented as mean 
±SEM.   
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Figure 2.3. Hypothalamic neuropeptide expression in Mbd2-/- mice. 
(A) Simplified diagram of the orexigenic AgRP-NPY and anorexigenic POMC neurons in the 
arcuate nucleus of the hypothalamus, which contribute to the regulation of food intake and energy 
expenditure. (B) The relative expression levels of Agrp and Npy in the hypothalamus are 
equivalent between wildtype and Mbd2-/- mice, but Pomc is significantly downregulated. Mbd2 is 
significantly downregulated and Mecp2 expression is unaffected in Mbd2-/- mice, as expected 
(Mbd2+/+ and Mbd2-/- n = 5, unpaired two-tailed t test with Holm-Sidak multiple comparison 
correction). All data are presented as mean ±SEM. 
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Figure 2.4. Mbd2-/- mice have equivalent biogenic amine content to wildtype littermates. 
HPLC analysis showed equivalent levels of biogenic amines and their metabolites in the cortex 
(A) and striatum (B) between 12 week old male Mbd2+/+ and Mbd2-/- mice (Mbd2+/+ n = 6, Mbd2-/- 
n = 8, unpaired two-tailed t test with Holm-Sidak multiple comparison correction). All data are 
presented as mean ±SEM.  
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Figure 2.5. RNA-seq from the striatum of Mbd2-/- mice confirms loss of Mbd2 exon 2 and 
expression of full-length transcript. 
RNA-seq tracks from two wildtype replicates (blue) and two Mbd2-/- (KO) replicates shows a loss 
of reads corresponding to exon 2, which is deleted in Mbd2-/- mice. Small amounts of read-
through transcript are detectable in the KO samples, as reported (Hendrich et al., 2001). 
 
 
 
Figure 2.6. Differentially expressed genes in the striatum of Mbd2-/- mice compared to 
wildtype littermates. 
MA plot showing differential gene expression and abundance from RNA-seq analysis of Mbd2-/- 
versus wildtype striatal tissue. Genes that are significantly differentially expressed (FDR < 0.05) 
are labeled in red. Selected and discussed genes are labeled. 
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Table 2.4. List of differentially expressed genes in the striatum of Mbd2-/- mice compared to 
wildtype littermates. 
All significantly DEGs (FDR < 0.05) and predicted functions are listed. Significantly differentially 
expressed genes with FC > log(1) are labeled in red.  
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CHAPTER 3: Genetic tagging of MBD2 reveals different spatiotemporal 
expression and supports distinct functions from related MBD proteins 
 
Adapted from: Wood, K. H., Johnson, B. S., Welsh, S. A., Lee, J. Y., Cui, Y., Krizman, E., 
Brodkin, E. S., Blendy, J. A., Robinson, M. B., Bartolomei, M. S., Zhou, Z. Tagging methyl-CpG 
binding domain proteins reveals different spatiotemporal expression and supports distinct 
functions. Epigenomics. In Press. 
 
ABSTRACT 
 
 DNA methylation and other epigenetic mechanisms are necessary to maintain cell-type 
specific gene expression programs and the chromatin state. However, it is not understood how 
DNA methylation is linked to the regulation of transcription and histone modifications. Previous 
biochemical studies have shown the methyl-DNA binding domain (MBD) family of proteins can 
bind to methylated DNA and recruit various co-repressor complexes to mediate transcriptional 
regulation. However, the in vivo roles of these proteins in a cellular context and their 
spatiotemporal expression patterns have not been fully determined. The study of the MBD 
proteins in vivo, and especially MBD2, has been limited by the lack of reliable antibodies. To 
overcome this limitation, we generated novel transgenic mice with endogenous MBD2 or MBD1 
tagged with biotin. This approach allowed us to isolate biotin-tagged MBD2 for multiple 
applications to characterize MBD2 in vivo functions in the context of the MBD protein family. We 
were also able to reliably distinguish multiple isoforms of tagged MBD2, which may have distinct 
biological properties. We determined that MBD2 interacts with the NuRD complex in multiple 
tissues in vivo. We also found that MBD2 is broadly expressed throughout multiple tissues at 
young and adult ages, in contrast to related proteins MBD1, MeCP2, and MBD3, which are 
primarily expressed in the brain. Our findings support a critical role for MBD2 in peripheral tissues 
and reveal new directions and genetic tools for the study of MBD protein in vivo functions. 
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INTRODUCTION 
 
Epigenetic mechanisms, including DNA methylation, are essential for the maintenance of 
chromatin state and gene expression programs (Smith and Meissner, 2013; Suzuki and Bird, 
2008). The mechanism by which DNA methylation is interpreted into transcriptional output is not 
fully understood, but involves protein ‘readers’ that bind to methylated sites (Du et al., 2015). 
These readers include the methyl-CpG binding domain (MBD) family of proteins, comprised of 
methyl-CpG binding protein 2 (MeCP2) and MBDs 1-6 (Du et al., 2015; Hendrich and Bird, 1998). 
The MBD is a highly conserved domain originally identified for its ability to specifically bind mCG 
sites (Meehan et al., 1989). Most MBD proteins, with the exception of MBD3, MBD5 and MBD6, 
bind to DNA in a methylation density-dependent manner when expressed in ESCs (Baubec et al., 
2013). 
Biochemical studies support the role of MBD proteins in mediating transcriptional 
repression through the recruitment of various co-repressor complexes (Feng and Zhang, 2001; 
Nan et al., 1998; Ng et al., 2000). MBD2 or MBD3 are incorporated into mutually exclusive 
complexes with the Mi2/nucleosome remodeling and deacetylase (NuRD) complex, while MeCP2 
associates with the repressive Sin3A and NCoR/SMRT complexes (Ebert et al., 2013; Le 
Guezennec et al., 2006; Lyst et al., 2013; Nan et al., 1998; Ng et al., 1999). MBD1 interacts with 
several heterochromatin-associated proteins, including repressive histone methyltransferases 
(Fujita et al., 2003c; Ichimura et al., 2005; Reese et al., 2003; Sarraf and Stancheva, 2004). 
However, the functional outcomes of these interactions in a cellular context have not yet been 
fully characterized. 
The study of MBD protein functions in vivo has been severely limited by the lack of 
appropriate antibodies. Consequentially, the majority of studies on MBD proteins, and especially 
MBD2, have relied on the use of tagged alleles overexpressed in cultured cells to perform various 
experiments such as chromatin immunoprecipitation and sequencing (ChIP-seq), amongst other 
applications (Baubec et al., 2013). While these studies provide insight into molecular mechanisms 
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of MBD protein function, they do not fully address MBD protein function in a complex, 
differentiated cellular context in vivo. 
In order to examine MBD functions in vivo, it is also necessary to identify the specific 
tissues or cell types where the MBD proteins are expressed. MBD expression at the 
transcriptional level has been assessed in several tissues for MeCP2, MBD1 and MBD2 
(Hendrich and Bird, 1998; Roloff et al., 2003). However, a closer analysis of MeCP2 expression 
showed that MeCP2 protein levels do not correlate with transcript abundance in mouse or human 
tissues, indicating that significant post-transcriptional regulation may be occurring (Shahbazian et 
al., 2002). Phenotypic data must also be carefully evaluated to determine the cell-type specific 
functions of MBD proteins. For example, MeCP2 loss-of-function phenotypes in non-neuronal 
tissues may be occurring due to non-cell-autonomous effects that are neuronal in origin, as was 
recently shown in a study of muscle (Conti et al., 2015). However, a comprehensive analysis of 
MBD protein expression in tissues of interest has not been possible due to limitations of currently 
available antibodies, especially for MBD2. 
In this study, we sought to explore the functions of MBD2 in vivo in the context of the 
other MBD family proteins. To investigate the underlying causes of the distinct behavioral and 
physiological outcomes of Mecp2, Mbd1, and Mbd2 null mice, we generated mouse lines with 
gene replacement alleles expressing endogenous MBD2 or MBD1 tagged with biotin. We used 
these mice to systematically identify the in vivo binding partners, genomic localization, and 
spatiotemporal expression patterns of MBD2 in the context of the MBD protein family. Our 
findings reveal new insights and directions and provide novel genetic tools for the study of MBD2 
function in vivo. 
 
METHODS 
 
Animal Husbandry 
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All experiments were conducted in accordance with the ethical guidelines of the US National 
Institutes of Health and with the approval of the Institutional Animal Care and Use Committee of 
the University of Pennsylvania. All mice were housed in a standard 12 h light/12 h dark cycle with 
access to ample amounts of food and water. All experiments were performed on mice on a 
congenic sv129:C57BL/6J background unless otherwise stated. All assays were performed on 
male littermates aged 2-3 months. Mice deficient in MBD2 (Mbd2-/-) or MBD1 (Mbd1-/-) are 
previously described (Hendrich et al., 2001; Zhao et al., 2003) and were genotyped using a PCR-
based strategy (Chapter 2 Methods). 
 
Generation of Tavi-tagged mice 
The targeting constructs used for homologous recombination in ESCs were cloned in two arms by 
PCR amplification of sv129 genomic DNA. The primer sequences used to PCR amplify the 5’ and 
3’ arms of Mbd2 and Mbd1, respectively, and the Tavi oligo are listed in Table 3.1.  
 
Table 3.1. Primers used to generate targeting constructs for Tavi-tagged alleles of Mbd2 
and Mbd1. 
 
The Tavi oligo contained a 5’ SacII restriction site overhang and a 3’ HpaI restriction site 
overhang and a stop codon directly upstream of the 3’ HpaI site overhang. Insertional 
mutagenesis was then used to introduce SacII and HpaI restriction sites into exon 6 of Mbd2 and 
exon 15 of Mbd1 in the respective targeting constructs. These sites were immediately upstream 
of the stop codon in order to ligate the Tavi tag oligo in the correct orientation at the C terminus of 
Primer  Forward Primer Reverse Primer 
Mbd2 5’ arm 5’-GTTTGGCTTAACACATCTCAACC-3’ 5’-GGATGAGTCAGGACAGAGGAGTA-3’ 
Mbd2 3’ arm 5’-GAAGCTCAGGGTATGGTCTCAC-3’ 5’-AAAGTATCACGCTCTGGTCCAT-3’ 
Mbd1 5’ arm 5’-GCTGCAGATCCAGACCTTTC-3’ 5’-TCCCTCATCCGAGTGTTCTC-3’ 
Mbd1 3’ arm 5’-AAAAGCTGGTCCCACTCTCC-3’ 5’-ATTTGGGCAGGCAACACAAG-3’ 
Tavi oligo 
5’-GGGAAAACCTGTATTTTCAGGGCGCC 
GGCCTGAACGACATCTTCGAGCTCAGAA
AATCGAATGGCACGAATAGGTT-3’ 
5’-AACCTATTCGTGCCATTCGATTTTCTG 
AGCCTCGAAGATGTCGTTCAGGCCGGC
GCCCTGAAAATACAGGTTTTCCCGC-3’ 
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each gene. After ligation of the Tavi oligo into the 3’arm of each construct, each arm was cloned 
into a vector containing a loxP-flanked neomycin cassette (Neo) and a diphtheria toxin A 
negative-selection cassette. Each targeting construct was confirmed by sequencing, linearized 
using NotI and subsequently electroporated into sv129 mouse ESCs. Two ESC clones each of 
Mbd2Tavi and Mbd1Tavi were independently injected into C57BL/6 blastocysts and subsequently 
transferred to pseudopregnant females. The resulting chimeric offspring were mated with 
C57BL/6J EIIa-Cre mice (The Jackson Laboratory) for embryonic deletion of the Neo cassette, 
and the agouti offspring were screened by PCR genotyping to confirm germ line transmission of 
the Mbd2Tavi or Mbd1Tavi. Germline transmitted Mbd2Tavi or Mbd1Tavi mice were backcrossed to 
C57BL/6J for at least 5 generations. Mice were genotyped using a PCR-based strategy to detect 
wildtype and Tavi-tagged alleles of Mbd2 and Mbd1. The genotyping primers sequences are 
listed in Table 3.2.  
 
Table 3.2. Primers used to genotype Mbd2Tavi and Mbd1Tavi mice. 
 
Nuclear extract preparation 
Tissues were minced on ice and homogenized in ice-cold lysis buffer (10mM HEPES pH 7.9, 
1.5mM MgCl2, 10mM KCl, 0.5% NP-40, 0.2mM EDTA, protease inhibitors). Nuclei were pelleted, 
washed and resuspended in nuclear extract (NE) buffer (20mM HEPES pH7.9, 1.5mM MgCl2, 
500mM KCl, 0.2mM EDTA, 10% glycerol, protease inhibitors). Nuclei were incubated in NE buffer 
at 4°C for two hours with rotation. Samples were cleared by ultracentrifugation with TLA 100.3 
rotor (Beckman Optima TL) at 4°C for 30 minutes and the supernatant taken for nuclear extract. 
Protein concentration was quantified using a modified Bradford assay (Bio-Rad). 
 
Primers Sequences Product Size 
Mbd2Tavi 5’- AAAGGCAAACAGGTCAGCCATTCC-3’ 5’- ACAGGAAGAGCGAGTCCAACAAGT-3’ 
Wildtype: 473bp 
Mbd2Tavi: 557bp 
Mbd1Tavi 5’-TTCCCACAGAGAACACTCGGATGA-3’ 5’-TAGCAGGTCTTCAGCACACTTGGA-3’ 
Wildtype: 535bp 
Mbd1Tavi: 619bp 
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Western blot 
Western blots were carried out and imaged with the LI-COR Odyssey Clx Infrared Imaging 
System following manufacturer’s protocols. 50ug of nuclear extract was loaded per lane. 
Antibodies and dilutions used in this study are as follows: Avi tag, Abcam ab106159, 1:5000 
(listed as anti-BirA, detects the minimal peptide substrate of biotin ligase BirA regardless of 
biotinylation status); Sin3A, Thermo Scientific PA1-870, 1:500; HDAC1, Abcam Ab7028, 1:2000; 
HDAC2, Cell Signaling 5113, 1:2000; HDAC3, Santa Cruz sc-11417, 1:1000; LaminB1, Santa 
Cruz sc-30264, 1:1000; TBLR1, Bethyl A300-408A, 1:1000; Chd4, Abcam ab70469, 1:1000; 
MTA2, Santa Cruz sc-9447, 1:200; H3, Abcam ab1791, 1:2000; MBD2, Diagenode CS-098-100, 
1:500; MBD1, Santa Cruz sc-10751, 1:200; MBD3, Santa Cruz sc-9402, 1:200; MeCP2, rabbit 
polyclonal antibody directed to the C-terminus of MeCP2, 1:1,000 (Zhou et al., 2006). Secondary 
antibodies are as follows: Streptavidin DyLight 800 conjugated, Thermo Scientific, 1:1000; 
donkey anti-rabbit IRDye 680RD, donkey anti-mouse IRDye 800CW, donkey anti-goat IRDye 
800CW, all from LI-COR Biosciences, 1:10,000.  
 
Immunoprecipitation 
1mg of nuclear extract was adjusted to 300µl total volume with NE buffer to perform IP in 
duplicate. Protein G Dynabeads or Streptavidin M-280 Dynabeads (Life Technologies) were 
washed three times in PBS with 0.1% Tween-20 and 0.1% BSA. Nuclear extracts were cleared 
for 30 minutes at 4°C with 25µl Protein G Dynabeads. For streptavidin pulldown, 50µl of 
streptavidin Dynabeads were added to the nuclear extract and incubated at 4°C for two hours 
with rotation. For antibody immunoprecipitation, 5µg of antibody was added to nuclear extract and 
incubated overnight at 4°C with rotation. 50µl of Protein G beads were blocked in wash buffer 
overnight at 4°C with rotation. Blocked beads were incubated with antibody-conjugated nuclear 
extract in the morning for two hours at 4°C with rotation. Beads were washed four times in PBS 
with 0.1% Tween-20 and split into two equal volumes. Each sample was resuspended in 25µl 
loading buffer with 50mM DTT and boiled for 10 minutes at 95°C prior to loading on gel. 
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Chromatin immunoprecipitation and qPCR 
Tissue was suspended in 10ml ice-cold crosslinking buffer (10mM HEPES pH 7.5, 100mM NaCl, 
1mM EDTA, 1mM EGTA, 1% formaldehyde) and homogenized with a Polytron tissue 
homogenizer (VWR). Homogenized tissue was rotated at room temperature for 5 minutes after 
which glycine was immediately added to a final concentration of 0.125M. Tissue was washed 
twice with ice-cold PBS, resuspended in lysis buffer 1 (50mM HEPES pH 7.5, 140mM NaCl, 1mM 
EDTA, 1mM EGTA, 0.25% Triton X-100, 0.5% NP-40, 10% glycerol, protease inhibitors) and 
dounced to lyse cells. Pelleted nuclei were washed and resuspended in lysis buffer 2 (10mM Tris 
pH 8.0, 1mM EDTA, 1mM EGTA, 0.25% SDS, protease inhibitors) and incubated on ice for 20 
minutes to lyse nuclei. Chromatin was sheared using a Covaris S220 to approximately 200-
500bp. Chromatin shearing efficiency was analyzed using agarose gel electrophoresis. 100µg of 
chromatin was diluted with lysis buffer without SDS to a final SDS concentration of 0.1% and 5µg 
was reserved as input. Chromatin was precleared with Protein A Dynabeads (Life Technologies) 
for 30 minutes with rotation at 4°C. For TEV protease pre-treatment, chromatin was incubated at 
this point with 20 units of TEV protease (Sigma-Aldrich) for 3 hours at 16°C before proceeding.  
Chromatin was incubated with 5µg of antibody or IgG control, or with 50µl of streptavidin 
Dynabeads overnight at 4°C with rotation. For antibody ChIP, 30µl of Protein A Dynabeads were 
washed and blocked overnight at 4°C with rotation in blocking buffer (1% BSA in TBST). For 
antibody ChIP, chromatin was incubated for 3 hours at 4°C with blocked Protein A beads. The 
antibodies used for ChIP are anti-histone H3 (acetyl K27) (Abcam ab4729), anti-histone H3 (tri-
methyl K4) (Abcam ab8580) and normal rabbit IgG (Cell Signaling 2729). Beads were washed as 
follows: once with low salt buffer (50mM HEPES pH 7.5, 150mM NaCl, 1mM EDTA, 1% Triton X-
100, 0.1% DOC), once with high salt buffer (50mM HEPES pH 7.5, 500mM NaCl, 1mM EDTA, 
1% Triton X-100, 0.1% DOC), once with LiCl buffer (10mM Tris-HCl pH 8.0, 1mM EDTA, 0.5% 
DOC, 0.5% NP-40, 250mM LiCl), and twice with TE buffer (10mM Tris pH 8.0, 1mM EDTA). Input 
and IP chromatin was eluted in 100µl elution buffer (50mM Tris pH 8.0, 10mM EDTA, 1% SDS) 
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overnight at 65°C to reverse crosslinks. DNA was treated with RNase A and proteinase K before 
phenol-chloroform purification following standard methods. DNA was quantified by Qubit 
Fluorometric Quantitation (Thermo Fisher Scientific). ChIP DNA was analyzed by qPCR using 
SYBR Green detection (Applied Biosystems) with the primers listed in Table 3.3.  
 
Table 3.3. Primers used for ChIP-qPCR. 
 
 
Fractionation of small intestine and colon crypts and protein lysate preparation 
The gastrointestinal tract was dissected on ice, cut longitudinally and washed in cold PBS. The 
villi of the small intestine were gently scraped off using a glass coverslip. Remaining tissue was 
minced and incubated in ice-cold 5mM EDTA/PBS for 30 minutes with pipetting every 5 minutes 
to release crypt cells. After letting tissue settle to bottom of tube, the supernatant was filtered 
through a 70µm filter and transferred to a new tube. This was repeated with additional PBS until 
100µl of supernatant was collected and cells were pelleted. Whole cell protein lysates were 
prepared by incubating cells in RIPA buffer (10mM Tris-HCl pH 8.0, 1mM EDTA, 0.5mM EGTA, 
1% Triton X-100, 0.1% DOC, 0.1% SDS, 140mM NaCl) with dounce homogenization. Samples 
were cleared by centrifugation and quantified using a modified Bradford Assay (Bio-Rad). 
 
Brain histology 
Locus Forward Primer Reverse Primer 
Gapdh 
Promoter 
5’- CCATCACGTCCTCCATCATC -3’ 5’- CAGTCGGAAACTGGGAAGG-3’ 
Actb 
Promoter 
5’- AGTGTCTACACCGCGGGAAT-3’ 5’- CTGGCACAGCCAACTTTACG-3’ 
IAP 
element 5’- GCTTTCGTTTTTGGGGCTTGG -3’ 5’- CTTACTCCGCGTTCTCACGAC-3’ 
Chr6 Gene 
Desert 5’- GGGAGAGAGTGATAGTCCAAGA -3’ 5’- CTTTGGTAGAAGAGAATGGTGTTTG-3’ 
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Mice were anesthetized with 1.25% Avertin (wt/vol), transcardially perfused with 4% 
paraformaldehyde (wt/vol), and brains were post-fixed for 2 hours at 4°C. Brains were washed in 
PBS, cryoprotected in 30% sucrose/PBS at 4°C overnight, and snap frozen in OCT mounting 
medium (Sakura Finetek). Frozen tissue was cryosectioned at 20µm and mounted on glass slides 
for staining. For β-galactosidase (β-gal) staining, sections were incubated in X-gal staining 
solution (5mM K3Fe(CN)6, 5mM K4Fe(CN)6, 2mM MgCl2, 0.01% DOC, 0.02% NP-40, 1mg/ml X-
gal in PBS) overnight at 37°C. Slides were rinsed five times in PBS and coverslipped. For Nissl 
staining, mounted frozen sections were dehydrated in ethanol and xylene, rehydrated, incubated 
in cresyl violet acetate solution (0.1% cresyl violet, 0.25% glacial acetic acid (v/v)) for 10 minutes 
at room temperature, rinsed, dehydrated and coverslipped. 
 
Gastrointestinal tract histology 
Small intestine and colon was cut longitudinally and washed in ice-cold PBS. Fresh tissue was 
snap-frozen in OCT mounting medium (Sakura Finetek), cryosectioned at 20µm and mounted on 
slides for staining. β-gal staining was performed as described for brain tissue. Sections were 
counter-stained with nuclear fast red (Sigma-Aldrich) following manufacturer’s protocols. 
 
RESULTS 
 
Generation of gene replacement alleles expressing biotin-tagged MBD2 or MBD1 
Given that previous studies linked MeCP2 and MBD1 to brain function in both humans 
and mice (Allan et al., 2008; Cukier et al., 2010; Goffin et al., 2012; Guy et al., 2001), it is 
surprising that mice lacking MBD2 are equivalent to control littermates on most measures, 
including behavior, gene expression, and biogenic amine levels (Chapter 2). MBD2 likely has 
critical functions in other tissues and systems, such as the gastrointestinal and immune systems 
(Cook et al., 2015; Sansom et al., 2003; Wang et al., 2013), that may contribute to the 
hypoactivity, impaired nesting and nurturing (Hendrich et al., 2001), and low body weight 
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phenotypes observed in Mbd2 null mice. However, the study of MBD2 functions in vivo has been 
impeded by the lack of reliable antibodies that specifically recognize MBD2.  
To overcome these limitations, we took a genetic approach and developed gene 
replacement alleles tagging MBD2 with a biotinylation consensus sequence derived from the E. 
coli biotin ligase, BirA (Figure 3.1). The tag was introduced to the C-terminus of MBD2 and 
consists of two parts: a tobacco etch virus (TEV) protease cleavage site and an avidin 
biotinylation consensus sequence that can be selectively biotinylated (Figure 3.1.A,B). We 
labeled this tag as the “Tavi” tag and the tagged allele as Mbd2Tavi. We also generated a separate 
transgenic mouse line with BirA constitutively expressed from the Rosa26 locus (R26BirA/+) 
(Johnson et al., manuscript in preparation). Therefore, MBD2Tavi protein can be specifically 
biotinylated in the presence of BirA (Figure 3.1.A,B). We can detect and pull down biotinylated 
endogenous MBD2 proteins using streptavidin-conjugated beads (Figure 3.1.C). Treatment with 
TEV protease cleaves off the biotinylated tag from the MBD2 protein (Figure 3.1.D). This set of 
transgenic mice allows us to detect and experimentally manipulate endogenous MBD2 with high 
specificity and reproducibility. 
Two previously described isoforms of MBD2, MBD2a and MBD2b (Hendrich and Bird, 
1998), carry the Tavi tag (Figure 3.2.A). These isoforms arise from alternative translation start 
sites from the same transcript that is expressed in adult somatic tissues (Hendrich and Bird, 
1998). MBD2a, but not MBD2b, includes a N-terminal GR repeat region. Post-translational 
methylation of the GR repeat has been shown to affect MBD2a function by reducing its affinity for 
DNA and the NuRD complex (Tan and Nakielny, 2006). MBD2Tavi also includes a transcriptional 
repression domain (TRD) that interacts with the NuRD complex (Boeke et al., 2000). Another 
isoform, MBD2c, is expressed exclusively in the testes and ESCs (Hendrich and Bird, 1998; Lu et 
al., 2014). MBD2c has an alternatively spliced C terminus that does not include the Tavi tag and 
is not depicted in Figure 3.2.A. Mice heterozygous or homozygous for Mbd2Tavi are viable and 
fertile similar to littermate controls. In contrast to Mbd2-/- mice that have reduced body weight 
(Figure 2.2.A), Mbd2Tavi/Tavi mice with or without BirA expression show equivalent body weight to 
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wildtype and R26BirA/+ littermates (Figure 3.2.B) and we have not observed any gross phenotypic 
abnormalities during routine handling. Therefore, biotinylation of MBD2Tavi does not appear to 
impair MBD2 function. 
We then used fluorophore-conjugated streptavidin to examine MBD2Tavi expression by 
western blot (Figure 3.2.C). A representative commercial antibody to MBD2 (and others, data not 
shown) recognizes several unknown proteins that do not differ between wildtype (WT) and Mbd2-
/- (KO) adult brain lysate (denoted by *), demonstrating invalidity of the stated antibody. In 
contrast, streptavidin detects three biotinylated MBD2Tavi isoforms with high specificity in 
Mbd2Tavi/Tavi; R26BirA/+ mice, but not in mice expressing BirA without MBD2Tavi (R26BirA/+). In 
addition to the predicted MBD2aTavi and MBD2bTavi isoforms, we observed a third MBD2 isoform 
slightly smaller than MBD2aTavi that has been previously detected but not described in detail (Ng 
et al., 1999). This isoform has the C-terminal Tavi tag and is biotinylated in the presence of BirA. 
Given the consistency and reproducibility of this isoform in different tissues and time points 
(Figure 3.9), it is unlikely to be a degradation product of MBD2aTavi. Therefore, we designated this 
novel isoform as MBD2d. It includes exon 6 where the Tavi tag is inserted and may occur through 
alternative splicing or translation start site usage (Figure 3.2.A). Direct comparison of proteins 
detected by the MBD2 antibody versus streptavidin (Figure 3.2.C, merged image) demonstrates 
the specificity and robustness of this biotin-tagging approach to identify MBD2 isoforms. 
In order to directly compare MBD2 to MBD1 in vivo, we employed the same approach 
and generated mice expressing gene replacement alleles for MBD1Tavi (Figure 3.3.A) and also for 
MeCP2 (Johnson et al., in preparation). Murine Mbd1 has three reported alternatively spliced 
isoforms that have two or three CxxC zinc finger DNA-binding domains in addition to a 
transcriptional repression domain (TRD) (Jørgensen et al., 2004). MBD1a and MBD1b both carry 
the Tavi tag, but MBD1c has an alternatively spliced C-terminus that does not include the Tavi tag 
(Fig. 5A). Mbd1Tavi/Tavi; R26BirA/+ mice are viable and fertile with no gross phenotypic abnormalities 
observed during routine handling. Using western blots, we found that an antibody against MBD1 
detects several cross-reacting proteins in postnatal day 7 (P7) brain lysate, comparing Mbd1 null 
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(KO) to WT mice (Figure 3.3.B, denoted by *) (Zhao et al., 2003). All three isoforms of MBD1, 
MBD1aTavi, MBD1bTavi and untagged MBD1d, are visible in R26BirA/+ and Mbd1Tavi/Tavi; R26BirA/+ 
mice when compared to Mbd1 null mice using this antibody. In contrast to R26BirA/+ mice and 
Mbd1 null mice, streptavidin detects two specific proteins corresponding to biotinylated MBD1aTavi 
and MBD1bTavi in lysate from Mbd1Tavi/Tavi; R26BirA/+ mice. Streptavidin also detects a 75kDa 
endogenously biotinylated protein that is close in size to untagged MBD1d (denoted by *). The 
merged image demonstrates that streptavidin specifically detects the two biotin-tagged MBD1Tavi 
isoforms that are also recognized by the MBD1 antibody (yellow bands) (Figure 3.3.B). In 
summary, this biotin-tagging approach represents a powerful tool to study multiple isoforms of 
endogenous MBD proteins, overcoming antibody limitations. 
 
Streptavidin-mediated pulldown of biotinylated MBD2Tavi detects multiple isoforms of 
MBD2 in several tissues 
 We first sought to compare our streptavidin-mediated approach to antibodies in the 
detection of biotinylated MBD2Tavi. We examined protein lysate from two tissues, brain and lung, 
from adult Mbd2Tavi/Tavi; R26BirA/+, R26BirA/+, and MeCP2Tavi/y; R26BirA/+ mice in order to compare 
biotinylated MBD2Tavi and MeCP2Tavi to mice that do not express any Tavi-tagged proteins. We 
should detect only endogenously biotinylated proteins in lysate from R26BirA/+ mice and therefore 
can reliably distinguish biotinylated Tavi-tag proteins from background. We used streptavidin 
pulldown to enrich for biotinylated proteins and detected each protein with streptavidin and 
antibodies raised against MBD2 or MeCP2, respectively (Figure 3.4). 
We observed that a commercial antibody to MBD2 detects multiple non-specific protein 
species in the brain and one notable non-specific protein in the lung that is close in size to MBD2 
(Figure 3.4.A,C; denoted by *). However, streptavidin-mediated pulldown of biotinylated MBD2Tavi 
reveals that this antibody detects only MBD2aTavi, and, furthermore, that this band is only 
detectable upon streptavidin-mediated enrichment of MBD2Tavi in both brain and lung (Figure 
3.4.A,C; note yellow band in merged image). The cross-reacting bands that are visible in the input 
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samples are depleted upon streptavidin-mediated enrichment of MBD2Tavi. In contrast, 
streptavidin reveals the three biotinylated isoforms of MBD2 described above in addition to a 
constitutively expressed endogenous biotinylated protein of 75kDa (denoted by *). Therefore, we 
conclude that our approach to detect biotinylated MBD2Tavi in vivo is significantly more robust and 
reliable than detection with antibodies alone. 
In contrast, an antibody raised against MeCP2 detects endogenous MeCP2 and 
biotinylated MeCP2Tavi with high specificity in protein lysate from both brain and lung (Figure 
3.4.B,D). We found that streptavidin detects a constitutively expressed, endogenously biotinylated 
protein of approximately 75kDa that is close is size to MeCP2 which is also enriched after 
streptavidin pulldown (Figure 3.4.B,D; denoted by *). By examining the merged image, it is 
apparent that both biotinylated MeCP2Tavi and MBD2Tavi are enriched by streptavidin pulldown, 
but only MeCP2Tavi is detected by the MeCP2 antibody (Figure 3.4.B,D; note yellow band in 
merged image).  
We also validated the specific enrichment of biotinylated MBD2Tavi and MeCP2Tavi by 
streptavidin pulldown using an additional reagent. We used an antibody raised against the 
biotinylation consensus sequence for BirA (labeled Avi) to detect the Tavi tag of MBD2Tavi and 
MeCP2Tavi in addition to streptavidin to detect biotinylated proteins. This approach allowed us to 
simultaneously detect MBD2Tavi and MeCP2Tavi using the same reagents for a direct comparison 
of enrichment and expression levels. We performed streptavidin pulldown using protein lysate 
from four tissues, brain, lung, small intestine, and colon, from adult Mbd2Tavi/Tavi; R26BirA/+, 
R26BirA/+, and MeCP2Tavi/y; R26BirA/+ mice in order to compare biotinylated MBD2Tavi and MeCP2Tavi 
to mice that do not express any Tavi-tagged proteins (Figure 3.5). This comparison allowed us to 
assess the presence of multiple isoforms of MBD2 in different tissues, and also served as a 
preliminary analysis of MBD protein spatial expression. 
We found that streptavidin and the Avi antibody detect three isoforms of MBD2Tavi in all 
tissues examined here. The Avi antibody also detects several cross-reacting proteins that vary 
between tissues, must notably a band at 50kDa in the brain and colon that partially obscures 
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MBD2aTavi and MBD2dTavi (Figure 3.5.A,D). Streptavidin also detects several endogenously 
biotinylated proteins, including one at 75kDa that partially obscures MeCP2Tavi in blots with brain, 
lung, and colon lysate (Figure 3.5.A,B,D). Despite these complications, it is apparent that MBD2 
and MeCP2 carry the Tavi-tag and are biotinylated, as demonstrated by the merged signals using 
two methods of detection, the Avi antibody and streptavidin (yellow bands, merged images). We 
also observed that MeCP2 expression is not detectable in the small intestine, even after 
enrichment for MeCP2Tavi with streptavidin pulldown (Figure 3.5.C). Additionally, we found that all 
three isoforms of MBD2Tavi appear to be equivalently expressed in these four tissues, which we 
later re-evaluated with further experiments (Figure 3.9). These additional verifications 
demonstrate the necessity for a novel affinity-tagging approach in order to study MBD2 functions 
in vivo. This approach also allows for the enrichment and detection of biotinylated MBD2Tavi and 
MeCP2Tavi in parallel. 
 
Streptavidin-mediated pulldown of biotinylated MBD2Tavi reveals distinct binding partners 
for MBD2 and MeCP2 in vivo and ubiquitous MBD2-NuRD interactions 
 Our initial analysis of MBD2Tavi and MeCP2Tavi expression while verifying the biotinylation 
of each protein showed that these proteins are co-expressed in several tissues, including the 
brain, lung and colon (Figure 3.5). Despite being co-expressed and having similar DNA-binding 
properties, the MBD proteins have distinct functions that may be conferred through interactions 
with distinct protein complexes in vivo (Baubec et al., 2013; Nan et al., 1998; Zhang et al., 1999). 
However, for MBD2 these interactions have only been verified using cell culture systems and the 
dynamics of these interactions in vivo have not been fully explored. Therefore, in order to verify 
MBD2 and co-repressor interactions in vivo, we performed streptavidin-mediated co-pulldown 
experiments with MBD2Tavi and MeCP2Tavi using brain and lung lysate from Mbd2Tavi/Tavi; R26BirA/+ 
and MeCP2Tavi/y; R26BirA/+, respectively, and R26BirA/+ adult mice. We assessed interactions 
between MBD2 and the NuRD that have been studied in cultured cells and interactions between 
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MeCP2 and the NCoR and SIN3A co-repressor complexes (Boeke et al., 2000; Ebert et al., 2013; 
Lyst et al., 2013; Nan et al., 1998; Zhang et al., 1999).  
We detected interaction between MeCP2Tavi and two core components of the NCoR 
complex, TBLR1 and HDAC3. We also detected interaction between MeCP2Tavi and HDAC1, 
which associates with NCoR and SIN3A, and SIN3A itself in both brain and lung (Figure 3.6.A,B). 
We found that MBD2Tavi had a strong association with components of the NuRD complex, 
including HDAC1, HDAC2 and MTA2 in both tissues. Interestingly, we found that MBD2 shows 
stronger association with HDAC1 compared to MeCP2 under these pulldown conditions. We also 
observed a weak interaction between MBD2Tavi and SIN3A, as has been reported (Boeke et al., 
2000). Neither MeCP2Tavi nor MBD2Tavi interacted with LaminB1, as expected (Baubec et al., 
2013).  
This approach also allowed us to determine if there are tissue-specific interactions 
between the MBD2, MeCP2 and co-repressor complexes. To analyze this question more closely, 
we also examined MBD2 interactions with NuRD in the colon in addition to the brain and lung of 
adult mice (Figure 3.6.C). These tissues are representative of cell types with MBD2 and MBD3 
co-expression (brain), MBD2 expression but not MBD3, or MBD2 expression with lowly 
detectable MBD3 expression (Figures 3.8 and 3.9). We found essentially identical patterns of 
interaction for MeCP2Tavi and MBD2Tavi in the brain and lung. Furthermore, we observed similar 
interactions between MBD2Tavi and components of the NuRD complex in the brain, lung and 
colon. This evidence suggests that these interactions are ubiquitous and may not have tissue or 
cell type specificity. These findings also raise important questions for the interactions between 
MBD2 and NuRD in tissues where MBD3 is not expressed, specifically the lung and colon. 
Because all isoforms of MBD2 carry the Tavi tag, we were unable to distinguish which 
isoforms were interacting with NuRD by streptavidin pulldown of MBD2Tavi. It has been reported 
that modifications to the N terminus of MBD2a can affect NuRD association (Tan and Nakielny, 
2006).Therefore, we wanted to test which isoforms of MBD2 interact with NuRD in vivo. We 
performed co-immunoprecipitation with antibodies against two NuRD components, CHD4 (also 
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known as Mi2-β) and HDAC1 with brain lysate from adult Mbd2Tavi/Tavi; R26BirA/+ mice (Figure 
3.6.D). Unexpectedly, we found that all three isoforms of MBD2Tavi are co-immunoprecipitated 
with CHD4 and HDAC1. MBD2dTavi showed weaker interaction with CHD4 and HDAC1 compared 
to MBD2aTavi and MBD2bTavi, but the lower expression of this isoform makes quantitative 
interpretation difficult. In addition, all three MBD2Tavi isoforms have significantly weaker interaction 
with CHD4 than HDAC1 under these conditions. We determined that we were not disrupting 
endogenous protein complex interactions by detecting CHD4 and HDAC1 interactions with other 
NuRD complex proteins, including HDAC2 and MTA2, and HDAC1 interaction with SIN3A. We 
conclude that in vivo MBD2 is associated with the NuRD complex in the brain. Additional 
experiments may reveal whether or under what circumstances MBD2a may have reduced 
interactions with NuRD in vivo, as has been reported (Tan and Nakielny, 2006). 
 
MBD2Tavi is depleted at genomic loci with chromatin marks associated with transcriptional 
silencing 
 Due to the limitations of antibodies for MBD2, previous attempts to perform chromatin 
immunoprecipitation (ChIP) for MBD2 have mainly relied on tagged alleles over expressed in 
cultured cells (Baubec et al., 2013; Günther et al., 2013; Menafra et al., 2014). These previous 
studies generally showed that MBD2 is localized at methylated CpG islands at transcription start 
sites, promoters, and exons. Interestingly, MBD2 binding is highly dependent on mCG density 
and is consequentially not enriched at highly methylated, low-density sites such as introns and 
intergenic regions. MBD2 and NuRD are also found at some actively transcribed loci, suggesting 
that more complex transcriptional regulation may be occurring beyond simple transcriptional 
repression associated with DNA methylation. 
 We wanted to determine if MBD2 shows similar patterns of localization in vivo by using 
streptavidin to perform ChIP for MBD2Tavi in adult cortex tissue. Using ChIP followed by 
quantitative PCR analysis, we examined MBD2 enrichment at two constitutively expressed loci, 
the promoters of Gapdh and Actb. We also assessed two transcriptionally repressed or gene poor 
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regions, including intra-cisternal A-type particle (IAP) elements and a gene desert region on 
chromosome 6. IAP elements are high-copy number long terminal repeat (LTR) transposons that 
are found throughout the genome and transcriptionally silenced by methylation (Walsh et al., 
1998). Although these sites are methylated, the mCG density is low and therefore MBD2 is not 
strongly enriched at IAP elements or other repetitive elements (Baubec et al., 2013). 
 In order to assess the chromatin state at each site, we first performed ChIP-qPCR for 
histone H3 lysine 4 trimethylation (H3K4me3) and histone H3 lysine 27 acetylation (H3K27ac), 
both of which are associated with transcriptional activation and open chromatin (Shlyueva et al., 
2014). As expected, we determined that H3K4me3 and H3K27ac are enriched at the promoters 
of Gapdh and Actb relative to the transcriptionally repressed IAP elements and gene desert loci 
(Figure 3.7.A). We then used streptavidin to perform ChIP-qPCR for MBD2Tavi at the same loci 
(Figure 3.7.B). We determined that MBD2Tavi is enriched at the transcriptionally silent or gene-
poor regions at IAP elements and in the gene desert region of chromosome 6 and is relatively 
depleted at the promoters of Gapdh and Actb. Streptavidin also binds to endogenously 
biotinylated proteins, although these proteins are not predicted to be chromatin-binding proteins 
and therefore are unlikely to interfere with MBD2Tavi ChIP (de Boer et al., 2003). 
In order to verify the specificity or the streptavidin ChIP approach for MBD2Tavi, we 
repeated the ChIP experiment with an additional pre-treatment with TEV protease before 
performing the ChIP. This pre-treatment cleaves the C-terminal biotinylation consensus sequence 
from the coding sequence of MBD2Tavi, and therefore should give no ChIP signal after streptavidin 
ChIP. We determined that pre-treatment with TEV protease effectively abolishes the ChIP signal 
for MBD2Tavi at all loci (Figure 3.7.B), thereby demonstrating the specificity of this approach. 
 
Distinct spatiotemporal expression patterns of endogenous MBD2 in contrast to MBD1, 
MeCP2 and MBD3 
Together with published studies (Cook et al., 2015; Sansom et al., 2003; Wang et al., 
2013), our results support a role for MBD2 in tissues or organs outside the brain, in notable 
 
 76 
contrast to MeCP2 and MBD1 (Chapter 2). In order to better understand MBD2 functions in vivo, 
we sought to characterize where and when MBD2 is expressed in comparison to other MBD 
proteins. This has previously been challenging because, even with reliable antibodies, the 
variable immunoreactivity of each antibody makes comparison of the expression levels for 
different MBD proteins difficult. In contrast, our biotin-affinity tag approach allows for direct, 
quantitative comparison of expression levels of MBD2 and MBD1. To better understand where 
and when MBD2 functions in vivo, we analyzed the expression patterns of MBD2, MBD1, 
MeCP2, and MBD3 across eight different tissues and two developmental time points, P7 and 
P42. We took advantage of the Tavi-tagged alleles of MBD2 and MBD1 to reliably determine the 
expression level of each protein and compared their expression side-by-side using quantitative 
western blots. This approach allowed us to obtain a comprehensive view of endogenous MBD 
spatiotemporal expression patterns at the protein level.  
Using MBD2Tavi mice with constitutively expressed BirA (Mbd2Tavi/Tavi; R26BirA/+), we 
analyzed the expression of three Tavi-tagged isoforms of MBD2 (MBD2a, MBD2b, and MBD2d) 
using two complementary reagents. First, we used an antibody raised against the biotinylation 
consensus sequence for BirA (labeled Avi) to detect the Tavi tag of MBD2Tavi. We also used 
streptavidin to detect biotinylated MBD2Tavi. In order to exclude cross-reacting proteins 
recognized by the Avi antibody and also exclude endogenously biotinylated proteins, we first 
used these reagents with protein lysate from R26BirA/+ animals that do not express any Tavi alleles 
(Figure 3.8.A,B). The Avi antibody detects several cross-reacting proteins, most notably a 50kDa 
protein that is highly expressed in the brain at both P7 and P42 and a weaker cross-reacting band 
at 37kDa at P7. Several endogenous biotinylated proteins are also detected by streptavidin in the 
molecular size around MBD2, particularly a 37kDa protein in the heart, liver, kidney and small 
intestine at P42 (Figure 3.8.A,B; denoted by *). 
Western blot analysis of protein lysate from Mbd2Tavi/Tavi; R26BirA/+ animals showed that all 
three isoforms of MBD2 are partially obscured by the cross-reacting bands detected by the Avi 
antibody, particularly in the brain (Figure 3.8.C,D). However, MBD2aTavi and MBD2bTavi are clearly 
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detected by streptavidin in multiple tissues at both P7 and P42. By examining the merged images 
from the streptavidin and Avi antibody signals (yellow bands), we concluded that the three 
isoforms of MBD2Tavi are expressed highly in multiple tissues including the heart, lung, liver, 
kidney and colon at P7 and P42. MBD2dTavi appears to be expressed at a lower level than the 2a 
and 2b isoforms in all tissues examined, particularly at P42. These isoforms are expressed in the 
brain, but at a lower level compared than other tissues. Interestingly, all MBD2Tavi isoforms are 
not expressed in spleen or small intestine at P7, but become up-regulated in these tissues at P42 
(Figure 3.8.C,D).  
We next sought to place MBD2 spatiotemporal expression patterns into the context of the 
MBD family. Therefore, we surveyed MBD1, MeCP2 and MBD3 expression in the same set of 
tissues and time points included in our MBD2 study. We used the Tavi-tag system to analyze 
MBD1 expression. First, we identified cross-reacting proteins detected by the Avi antibody and 
endogenously biotinylated proteins by analyzing protein lysate from R26BirA/+ animals (Figure 
3.9.A,B). At the molecular size around MBD1, the Avi antibody detected only a minor cross-
reacting band at 75kDa in the kidney at P42 (denoted by *). Several endogenous biotinylated 
proteins are detected by streptavidin, particularly a 75kDa protein with significant expression in all 
tissues examined at P7 and P42 (denoted by *) (Figure 3.9.A,B). 
We then used Mbd1Tavi/Tavi; R26BirA/+ mice to perform western blots with streptavidin and 
the Avi antibody to detect biotinylated MBD1Tavi expression (Figure 3.9.C,D). Streptavidin and the 
Avi antibody both detect biotinylated MBD1aTavi and MBD1bTavi. In order to examine the untagged 
MBD1d isoform, we also performed western blots with an antibody against MBD1 and included 
brain lysate from Mbd1 null mice to specifically identify MBD1 isoforms (Figure 3.9.C,D). The 
MBD1 antibody detects the untagged MBD1d isoform in addition to the two biotinylated Tavi-
tagged isoforms (MBD1 antibody and streptavidin merged images, note red unbiotinylated 
MBD1d band). We found that at P7, the three MBD1 isoforms are all highly expressed in the 
brain, consistent with a previously reported role for MBD1 in neural stem cells (Liu et al., 2010). 
Notably, MBD1 is barely detectable in non-neuronal tissues at P7. In addition, the expression of 
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all MBD1 isoforms is significantly reduced in P42 brains compared to P7 while remaining nearly 
undetectable in other tissues.  
We then assessed MeCP2 and MBD3 expression in P7 and P42 wildtype animals using 
antibodies against each protein (Figure 3.10). The specificity and reliability of these antibodies 
allowed us to complete the expression survey. Consistent with previous findings (Shahbazian et 
al., 2002), we found that MeCP2 is highly expressed in the brain at P7 and P42, but is also 
expressed relatively highly in the lung and colon. Developmentally, MeCP2 expression is up-
regulated in the heart and liver but down-regulated in the lung, kidney and colon in adult tissues, 
while remaining consistently high in the brain (Figure 3.10.A,B). Strikingly, we found that MBD3 is 
highly expressed in the brain with weakly detectable expression in the colon at P7 with 
undetectable expression in all other tissues examined (Figure 3.10.C). Similarly to MBD1 (Figure 
3.9.D), MBD3 is significantly downregulated in the brain at P42 while remaining undetectable in 
all other tissues with the exception of the colon (Figure 3.10.D). These findings are in notable 
contrast to the expression patterns of MBD2, which is widely expressed in multiple tissue types. 
Our side-by-side comparison of MBD expression levels reveals that MBD2 is distinct from MBD1, 
MeCP2, and MBD3 in that it is highly expressed across multiple non-neuronal tissues. In contrast, 
MBD1, MeCP2, and MBD3 are highly enriched in the brain, consistent with their well-described 
neuronal functions (Allan et al., 2008; Guy et al., 2001). Our findings on the spatiotemporal 
expression patterns of the MBD proteins are summarized in Figure 3.11. 
Our biotin-tagging approach also allows for direct quantitative comparison of MBD2Tavi 
and MBD1Tavi protein expression by measuring the streptavidin signal, an approach that is not 
possible with different antibodies. We quantified the relative expression of MBD2aTavi and 
MBD1aTavi by normalizing the streptavidin signal to the H3 antibody signal for the brain, lung, and 
colon at P7 and P42, three tissues where both MBD2 and MBD1 expression were detected 
(average of three representative western blots) (Figure 3.12). This analysis demonstrated that 
MBD2aTavi is expressed significantly higher in the lung and colon compared to the brain at both 
developmental time points, P7 and P42 (Figure 3.12.A). In contrast, MBD1aTavi is expressed 
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significantly higher in the brain compared to the lung and colon at P7 and P42 (Figure 3.12.B). 
We also assessed the temporal expression changes for MBD2aTavi and MBD1aTavi specifically in 
the brain (Figure 3.12.C). We found that MBD2aTavi expression levels in the brain do not 
significantly change from P7 to P42, but MBD1aTavi is significantly down-regulated at P42 
compared to P7. In P42 brains, though the expression of MBD2aTavi is significantly higher than 
MBD1aTavi, it is relatively lower than MeCP2 (Figure 3.12.C and 3.10.B). Together, the distinct 
spatiotemporal expression patterns of MBD2 in comparison to MBD1 and MeCP2 appear to 
underlie the distinct behavioral phenotypes observed in each individual MBD gene null mouse 
model. 
 
MBD2 is expressed widely throughout the brain and specifically in small intestine and 
colon epithelial crypt cells in adult mice 
 In order to examine MBD2 spatial expression in more detail, we took advantage of the 
Mbd2 null allele, which contains a LacZ allele that replaces the Mbd2 coding exon 2 (Hendrich et 
al., 2001). Therefore, we were able to use Mbd2-/- mice with β-gal staining to visualize where 
endogenous MBD2 is expressed. A similar approach has been used to determine MBD1 
expression in the brain, as the Mbd1 null allele also contains a LacZ allele (Zhao et al., 2003). We 
examined β-gal staining throughout the brain, including the olfactory bulb, prefrontal cortex, 
striatum, hippocampus, and cerebellum in P60 wildtype and Mbd2-/- mice. We also used Nissl 
staining of adjacent cryosections to visualize the anatomy of each region. In wildtype mice, no β-
gal staining is visible, as expected (Figure 3.13.A). In Mbd2-/- mice, we observed β-gal staining 
throughout the brain, which implies that MBD2 is endogenously expressed throughout all brain 
regions examined here (Figure 3.13.B). Certain regions such as the hippocampus and the 
cerebellum show intense staining, but this is reflective of higher cell density rather than increased 
MBD2 expression as increased staining intensity is also observed with Nissl staining. These 
results corroborate our findings that MBD2 is expressed in the adult mouse brain using western 
blots to detect MBD2Tavi expression (Figure 3.8).  
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 We also extended our analysis of MBD2 spatial expression to the gastrointestinal tract, 
as there is evidence that the regulation of DNA methylation is essential in the maintenance of 
epithelial crypt cells (Sheaffer et al., 2014). Additionally, MBD2 has been proposed to affect 
tumorigenesis in colorectal cancer models (Sansom et al., 2003). We used the same β-gal 
staining strategy with Mbd2-/- mice as for the brain and examined MBD2 expression in the 
jejunum of the small intestine and the colon of P60 wildtype and Mbd2-/- mice. We found that 
MBD2 is expressed specifically in the crypt epithelial cells in the small intestine and colon, which 
house proliferating undifferentiated stem cells (Figure 3.14.A) (Humphries and Wright, 2008; Tan 
and Barker, 2014). We also verified the spatial expression of MBD2 by fractioning epithelial cells 
from the small intestine into villi and crypt populations and isolating colon crypt epithelial cells 
from R26BirA/+ and Mbd2Tavi/Tavi; R26BirA/+ mice for western blot analysis. Using the anti-Avi 
antibody and streptavidin to detect MBD2Tavi by western blotting, we determined that MBD2 is 
expressed specifically in the crypt cellular populations of the small intestine and colon with 
undetectable expression in small intestine villi (Figure 3.14.B). Together, this evidence suggests 
that in the gastrointestinal tract MBD2 may have a specific role in proliferating crypt epithelial 
stem cells. 
 
DISCUSSION 
 
 In this study, we describe a novel biotin-tagging system for MBD2 and MBD1 and 
demonstrate the utility of this system for the study of MBD functions in vivo. We found that an 
affinity-tagged allele of MBD2 allows for the detection and immunoprecipitation of MBD2 in order 
to examine different protein isoforms, in vivo binding partners, chromatin localization, and 
spatiotemporal expression patterns. We found that MBD2 interacts with a distinct set of protein 
partners compared to MeCP2 in vivo, and is anti-correlated with the presence of activating 
histone marks at certain genomic loci. We also found that MBD2 is highly expressed in many 
tissues and that MBD2 expression increases significantly in spleen and small intestine in adult 
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mice. In contrast, MBD1, MeCP2, and MBD3 are primarily expressed in the brain. This study 
provides new genetic tools and identifies new areas for future studies of MBD function in vivo. 
 To investigate the in vivo function and expression of MBD2 in context of the MBD protein 
family, we used a biotin-tagging approach that we also applied to MBD1 (Figures 3.2 and 3.3). 
This approach advantageously allows for the precise detection of MBD2 from multiple tissues in 
vivo, while avoiding unreliable antibodies that are especially problematic for MBD2. We were also 
able to identify multiple isoforms of MBD2 that are not recognized by MBD2 antibodies alone 
(Figure 3.4). It is especially important to differentiate between the isoforms of MBD2 in vivo, as 
there is strong evidence that different isoforms of MBD2 have different interactions with the NuRD 
complex and different functions, particularly in ESCs (Lu et al., 2014; Tan and Nakielny, 2006). 
The MBD2d isoform has been observed in HeLa cells expressing endogenous MBD2 and is 
consistently identified in all tissues examined in this study (Figure 3.8). Therefore, it is unlikely to 
be a simple protein degradation product due to technical artifacts and may represent a cleavage 
event or post-translational modification of MBD2a. This isoform is also unlikely to arise from an 
alternatively transcribed or spliced transcript because previous examination of MBD2 in cDNA 
libraries identified only the transcripts corresponding to MBD2a/b and MBD2c (Figure 3.2.A) 
(Hendrich and Bird, 1998).  
 Previous studies have established that MBD2 is a key component of the NuRD complex, 
while MeCP2 is associated with the NCoR/SMRT and SIN3A co-repressor complexes, amongst 
other functions (Lyst et al., 2013; Nan et al., 1998; Ng et al., 1999; Zhang et al., 1999). However, 
in the case of MBD2, these results are exclusively from cultured cells and little is known about 
MBD2 in vivo functions. The Tavi-tag approach we developed allowed us to determine that MBD2 
is associated with NuRD in vivo, and under these conditions has stronger interactions with 
HDAC1 than MeCP2 (Figure 3.6.A,B). We found essentially equivalent results in the brain, lung, 
and colon, which suggests that the interactions of MBD2 with NuRD are ubiquitous. There is 
evidence that post-translational modifications of MBD2a specifically affect NuRD interactions 
(Tan and Nakielny, 2006). However, our co-immunoprecipitation results do not support this as we 
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found that all isoforms of MBD2 are associated with the NuRD complex (Figure 3.6.D). It is 
possible that this specific post-translational modification does not occur in the brain in vivo, or that 
there are additional regulatory mechanisms determining MBD2 interactions with NuRD. 
 Previous work on the genome-wide binding patterns of MBD2 have been limited to 
cultured cells, often with over-expressed alleles of MBD2, similar to studies of MBD2 binding 
partners (Baubec et al., 2013; Günther et al., 2013; Menafra et al., 2014). We used the Tavi-tag 
approach to perform ChIP-qPCR for MBD2 to better understand where MBD2 is localized in vivo. 
Previous studies have found that MBD2 is localized at areas of high mCG density, but is also 
associated with active transcription. The localization of MBD2 to actively transcribed sites may 
depend on interactions with NuRD (Baubec et al., 2013). We found that MBD2Tavi shows reduced 
binding at the enhancers of constitutively active genes that have activating histone marks 
compared to gene-poor inactive regions (Figure 3.7). This result supports previously published 
findings. However, in order to have a complete understanding of MBD2 function additional loci 
must be examined. The NuRD complex and other co-repressors may function as modulators of 
transcriptional activity instead of just repressors, which is supported by ChIP-seq data (Baubec et 
al., 2013; Reynolds et al., 2013). Therefore, it would be informative to compare MBD2 binding at 
constitutively active genes to genes that have more active modulation of their expression, such as 
lowly expressed or cell-type specific genes. Additionally, MBD2 binding and mCG density in vivo 
could be examined to determine if MBD2 binds to DNA in a mCG-density dependent manner, as 
has been shown in ESCs (Baubec et al., 2013). 
We also used the Tavi-tag approach to quantitatively analyze the different spatiotemporal 
expression patterns of MBD2 and MBD1 and compared these results to parallel analysis of 
MeCP2 and MBD3 using antibodies (Figures 3.8-12). This strategy allowed us to perform a side-
by-side, quantitative comparison of MBD2 and MBD1 expression, while avoiding the use of 
unreliable antibodies for MBD2. Our spatiotemporal expression survey demonstrates that MBD2 
is distinct from MBD1, MeCP2, and MBD3 as it is highly expressed in many tissues instead of 
being primarily expressed in the brain. We also observed that the three isoforms of MBD2 do not 
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show appreciable differences in expression levels between tissues or temporally, and instead are 
co-expressed consistently. 
In order to gain a more precise spatial map of MBD2 expression in the brain, we 
performed β-gal staining in Mbd2-/- mice (Figure 3.13). Our results show that MBD2 is expressed 
constitutively throughout all regions of the brain examined. This result is congruent with our 
western blot data that MBD2 is expressed constitutively when examined at the resolution of 
western blots with whole tissue lysate (Figure 3.8). The finding that MBD3 is nearly exclusively 
expressed in the brain result is especially striking, as MBD3 and MBD2 form mutually exclusive 
complexes with the NuRD complex (Le Guezennec et al., 2006). A recent study found that MBD3, 
but not MBD2, interacts with a brain-specific NuRD component CHD5, as opposed to CHD4 
(Potts et al., 2011). This finding further supports the hypothesis that NuRD-related functions in the 
brain may be primarily mediated by MBD3 and not MBD2. To extend this hypothesis, it is possible 
that in peripheral tissues MBD2 is the primary component of NuRD where MBD3 is not 
expressed. Our results show that MBD2 interacts with NuRD in a ubiquitous fashion across three 
tissues with variable MBD3 expression (Figure 3.6). Because MBD3 is not expressed or 
undetectable in these tissues, we hypothesize that NuRD primarily interacts with MBD2 in these 
cell types. 
Our finding that MBD2 expression increases significantly in the spleen and small intestine 
from P7 to P42 is intriguing in the context of previous studies on the role of MBD2 in immunity 
and the small intestine (Figure 3.8.C,D) (Berger et al., 2007; Cook et al., 2015; Phesse et al., 
2008; Sansom et al., 2003; Wang et al., 2013; Zhong et al., 2014). Precise temporal control of 
methylation and demethylation is essential for the development and differentiation of both T cells 
(Sellars et al., 2015) and intestinal epithelial crypt cells (Sheaffer et al., 2014), indicating that 
MBD2 may contribute to the interpretation of DNA methylation in these tissues. For example, 
MBD2 has a role in T cell development that is partially dependent on the methylation status of 
critical genes such as Foxp3 (Lal et al., 2009; Wang et al., 2013). MBD2 can also indirectly affect 
T cell activation and differentiation through its functions in dendritic cells (Cook et al., 2015). 
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Interestingly, both MeCP2 and MBD1 have also been implicated in innate and adaptive immunity 
(Cronk et al., 2015; Theoharides et al., 2015; Waterfield et al., 2014) indicating that MBD family 
proteins may have a wider role in these systems. However, although it is apparent that NuRD is 
essential for lymphocyte development, a precise role for MBD3 in these processes has not been 
identified (Dege and Hagman, 2014b).  
In the intestine, loss of MBD2 is linked to altered gene expression (Berger et al., 2007). 
MBD2 has also been identified as a potential target for cancer therapeutic intervention. Loss of 
MBD2 is protective against tumorigenesis in a mouse model of colorectal cancer by 
downregulating Wnt signaling (Phesse et al., 2008; Sansom et al., 2003). In addition, MBD2 
contributes to silencing of aberrantly hypermethylated tumor suppressor genes linked to colon 
cancer (Martin et al., 2008). Our results show that MBD2 is upregulated in the adult small 
intestine compared to expression at P7 (Figure 3.8.C,D). More specifically, we used parallel 
approaches to show that MBD2 is expressed in the proliferating, undifferentiated crypt stem cells 
of the small intestine and colon, and is not detectable in the differentiated epithelial villi cells of 
the small intestine (Figure 3.14). These results indicate that MBD2 may have a role specifically in 
undifferentiated, proliferating cells in this tissue. MBD3 has an essential role in maintaining gene 
expression programs and cell proliferation in the colon (Aguilera et al., 2011). MBD2 may have 
similar functions in the gastrointestinal tract. However, it is important to note that the histology of 
the small intestine and colon in Mbd2-/- mice appears equivalent to wildtype in our preliminary 
results and further work is required to characterize any MBD2-related phenotypes in this tissue. 
The results of this work reveal many new directions for the study of MBD2 in vivo 
functions. First, further investigation is necessary to characterize the MBD2d isoform we 
observed in multiple tissues at young and adult time points and to determine if this isoform is 
biologically relevant (Figure 3.8). For example, certain treatments to remove chemical 
modifications may reveal if MBD2d is simply an unmodified form of MBD2a that consequentially 
has a lower molecular weight. Additional work to investigate the in vivo binding partners of MBD2 
is also required to determine the dynamics of interactions between NuRD and MBD2 or MBD3. A 
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previous study suggested that most NuRD is in complex with MBD3 and not MBD2 in mammalian 
cells (Zhang et al., 1999). This may be the case in vivo in cell types where MBD2 and MBD3 are 
co-expressed including the brain and colon, but it is unclear how these interactions may differ in 
most peripheral tissues where MBD3 expression is very low.  
The transgenic mice developed in this study could also be used to further examine MBD2 
genome-wide localization patterns using streptavidin-mediated ChIP-seq. This approach would 
allow for a more thorough characterization of MBD2 localization, especially in conjunction with 
additional histone mark ChIP-seq analysis. These experiments may be combined with additional 
ChIP-seq or gene expression analysis in Mbd2 null mice in order to examine how loss of MBD2 
may affect the chromatin state and particularly histone acetylation. The Tavi-tag system can also 
be modified to allow for cell-type specific biotinylation of the tagged proteins. With conditional 
expression of BirA biotin ligase under control of a cell-type specific Cre recombinase, any of the 
experiments described here may be performed in a cell-type specific manner. This approach may 
be especially applicable to tissues such as the small intestine where MBD2 is expressed in a 
distinct sub-population of the tissue (Figure 3.14).  
 In summary, our study describes the in vivo binding partners and spatiotemporal 
expression patterns for MBD2 relative to the related proteins MBD1, MeCP2 and MBD3. We 
found that MBD2 is associated with a unique set of co-factors compared to MeCP2 in vivo and 
MBD2 localization to chromatin is anti-correlated with activating transcription marks. In contrast to 
MBD1, MeCP2, and MBD3, MBD2 is widely expressed in non-neuronal peripheral tissues. Our 
findings provide new insights into the functions of MBD2 and also provide genetic tools to 
investigate these functions in vivo. 
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CHAPTER 3 FIGURES 
 
 
 
Figure 3.1. Schematic of biotin-affinity tagging approach. 
(A) Mbd2Tavi/Tavi mice express an allele of MBD2 with a C-terminal biotinylation consensus 
sequence. (B) MBD2Tavi is constitutively biotinylated in the presence of BirA biotin ligase in 
Mbd2Tavi/Tavi; R26BirA/+ mice. (C) Biotinylated MBD2Tavi can be pulled down with streptavidin-
conjugated beads for further downstream applications. (D) Treatment with TEV protease cleaves 
MBD2Tavi between the endogenous protein coding sequence and C-terminal biotin consensus 
sequence. Schematic diagrams are not to scale. 
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Figure 3.2. Development of Mbd2Tavi knockin mice. 
(A) Targeting strategy for generating Mbd2Tavi knockin mice. The Tavi tag is inserted into exon 6. 
Two documented isoforms from alternative translation start sites, MBD2aTavi and MBD2bTavi, are 
expressed. A third newly found isoform, MBD2d, is also Tavi-tagged and expressed (GR, GR 
repeat region; TRD, transcriptional repression domain). (B), Mbd2Tavi/Tavi (n = 8) and Mbd2Tavi/Tavi; 
R26BirA/+ (n = 7) mice have equivalent body weight to wildtype (+/+, n = 7) and R26BirA/+ (n = 5) 
mice (two-way ANOVA). Data are presented as mean ±SEM. (C) Detection of MBD2 isoforms in 
the brain. An antibody against MBD2 detects cross-reacting bands in wildtype (WT) and Mbd2-/- 
(KO) brain lysate. Three isoforms of MBD2Tavi are specifically biotinylated and detected by 
streptavidin in Mbd2Tavi/Tavi; R26BirA/+, but not R26BirA/+, brain lysate. Cross-reacting and 
endogenously biotinylated proteins are denoted by *. 
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Figure 3.3. Development of Mbd1Tavi knockin mice. 
(A) Targeting strategy for generating Mbd1Tavi knockin mice. The Tavi tag is inserted into exon 15, 
which is included in MBD1aTavi and MBD1bTavi, but not in the alternatively spliced isoform MBD1d 
(CxxC, CxxC zinc finger DNA-binding domain; TRD, transcriptional repression domain). (B) An 
antibody against MBD1 detects three MBD1 isoforms that are present in R26BirA/+ and 
Mbd1Tavi/Tavi; R26BirA/+, but not Mbd1-/- (KO), P7 brain lysate. Two MBD1Tavi isoforms are 
biotinylated and detected by streptavidin specifically in lysate from Mbd1Tavi/Tavi; R26BirA/+ mice 
(merged image, yellow bands). Cross-reacting and endogenously biotinylated proteins are 
denoted by *.  
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Figure 3.4. Streptavidin-mediated pulldown of biotinylated MBD2Tavi compared to detection 
of MBD2 with an antibody. 
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Figure 3.4. Streptavidin-mediated pulldown of biotinylated MBD2Tavi compared to detection 
of MBD2 with an antibody. 
(A) Streptavidin pulldown of biotinylated MBD2Tavi from brain lysate reveals three isoforms of 
MBD2Tavi. Only MBD2aTavi is detected by an antibody against MBD2 after enrichment. (B) 
Streptavidin pulldown of MeCP2Tavi from brain lysate shows specific detection of MeCP2Tavi with 
an antibody against MeCP2. Streptavidin detects an endogenously biotinylated protein at 75kDa 
that partially obscures MeCP2. (C) Streptavidin pulldown of biotinylated MBD2Tavi from lung lysate 
reveals three isoforms of MBD2Tavi. Only MBD2aTavi is detected by an antibody against MBD2 
after enrichment. (D) Streptavidin pulldown of MeCP2Tavi from lung lysate shows specific 
detection of MeCP2Tavi with an antibody against MeCP2. Cross-reacting and endogenously 
biotinylated proteins are denoted by *. 
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Figure 3.5. Different isoforms of biotinylated MBD2Tavi can be detected with streptavidin in 
multiple tissues. 
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Figure 3.5. Different isoforms of biotinylated MBD2Tavi can be detected with streptavidin in 
multiple tissues. 
(A) Streptavidin pulldown and western blot with of biotinylated MBD2Tavi from brain lysate reveals 
three isoforms of biotinylated MBD2Tavi and biotinylated MeCP2Tavi. In the brain, a non-specific 
cross-reacting band detected by the Avi antibody partially obscures MBD2aTavi and MBD2dTavi. 
MeCP2Tavi is partially obscured by an endogenous biotinylated protein of 75kDa. (B) Biotinylated 
isoforms of MBD2Tavi and MeCP2Tavi are detected by streptavidin and Avi antibody and enriched 
with streptavidin pulldown in lung lysate. (C) Three isoforms of MBD2Tavi are detected by 
streptavidin and Avi antibody and enriched with streptavidin pulldown in small intestine lysate. 
MeCP2 is not detectable in the small intestine. (D) Three isoforms of MBD2Tavi and MeCP2Tavi are 
detected by streptavidin and Avi antibody and enriched with streptavidin pulldown in colon lysate. 
Cross-reacting and endogenously biotinylated proteins are denoted by *. 
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Figure 3.6. Distinct in vivo binding partners of MBD2 and MeCP2 in the brain and lung and 
ubiquitous MBD2-NuRD interactions across tissues. 
Streptavidin pulldown and western blot from brain (A) and lung (B) lysate shows strong 
interactions between MBD2Tavi and components of the NuRD complex, including HDAC1, HDAC2 
and MTA2. MBD2Tavi interacts weakly with SIN3A. MeCP2Tavi interacts with the NCoR complex, 
including TBLR1 and HDAC3, and weak interaction with HDAC1 and SIN3A. Neither protein 
interacts with LaminB1 as expected. (C) MBD2 interacts with the NuRD complex in the colon 
similarly to the brain and lung. (D) Three isoforms of MBD2Tavi are co-immunoprecipitated with 
components of the NuRD complex, including CHD4 and HDAC1. MBD2Tavi shows weaker 
interaction with CHD4 compared to HDAC1. Interactions between other components of the NuRD 
complex, including HDAC2 and MTA2, and between HDAC1 and SIN3A were verified as controls. 
Cross-reacting and endogenously biotinylated proteins are denoted by *. 
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Figure 3.7. MBD2 is depleted at genomic loci with activating histone marks. 
(A) ChIP-qPCR analysis in the cortex of adult Mbd2Tavi/Tavi; R26BirA/+ mice for activating histone 
marks H3K4me3 and H3K27ac shows enrichment at constitutively expressed loci, including the 
Gapdh and Actb promoters, and relatively lower enrichment at transcriptionally inactive regions, 
including IAP elements and a gene desert region of chromosome 6 (n = 3 biological replicates). 
(B) Streptavidin ChIP-qPCR in the cortex of adult Mbd2Tavi/Tavi; R26BirA/+ mice shows MBD2Tavi is 
enriched at transcriptionally repressed repetitive and intergenic regions, and depleted at loci with 
enrichment of activating histone marks including Gapdh and Actb promoters. Pre-treatment with 
TEV protease cleaves the Tavi tag and returns the ChIP signal to background levels, 
demonstrating specificity of streptavidin ChIP with Tavi-tagged MBD2 (n = 3 biological replicates). 
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Figure 3.8. Spatiotemporal expression of MBD2 at P7 and P42. 
(A) and (B) Western blot analysis with lysate from R26BirA/+ mice reveals cross-reacting proteins 
detected by the Avi antibody and endogenously biotinylated proteins detected by streptavidin, 
denoted by *. (C) and (D) Three isoforms of MBD2Tavi (MBD2aTavi, MBD2bTavi and MBD2dTavi) are 
biotinylated and detected by streptavidin and the Avi antibody. All isoforms of MBD2Tavi are highly 
expressed throughout the body at P7, but are not expressed in spleen and small intestine. All 
isoforms of MBD2Tavi are highly expressed throughout the body at P42, with up-regulation in 
spleen and small intestine compared to P7.  
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Figure 3.9. Spatiotemporal expression of MBD1 at P7 and P42. 
(A) and (B) Western blot analysis with lysate from R26BirA/+ mice reveals cross-reacting proteins 
detected by the Avi antibody and endogenously biotinylated proteins detected by streptavidin, 
denoted by *. (C) and (D) Two isoforms of MBD1Tavi (MBD1aTavi and MBD1bTavi) are biotinylated 
and detected by the Avi antibody and streptavidin. An antibody against MBD1 also detects 
MBD1d, compared to Mbd1 null brain lysate (KO brain). All three isoforms are highly expressed in 
the brain and show down-regulation at P42 compared to P7. 
 
 
 
Figure 3.10. MeCP2 is consistently highly expressed in the brain while MBD3 is 
downregulated in the adult brain. 
(A) and (B), MeCP2 is highly expressed in the brain at P7 and P42 as detected by an antibody 
against MeCP2 using lysate from wildtype animals. MeCP2 is also expressed in other tissues 
including the lung and colon. (C) and (D), MBD3 is highly expressed as a doublet band in the 
brain at P7 with lowly detectable expression at P42. MBD3 is also lowly detectable in the colon at 
P7 and P42.  
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Figure 3.11. Summary of MBD protein spatiotemporal expression patterns.  
In the brain, MeCP2, MBD1, MBD2 and MBD3 are highly expressed at P7, but only MeCP2 and 
MBD2 remain highly expressed at P42. In other tissues, MBD1 and MBD3 are undetectable with 
the exception of the colon. MBD2 is highly expressed across all tissues examined, and is 
upregulated in the spleen and small intestine at P42 compared to P7. 
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Figure 3.12. Quantification of MBD2aTavi and MBD1aTavi expression levels. 
Expression levels of biotinylated MBD2aTavi and MBD1aTavi were determined by normalizing the 
fluorescence levels of streptavidin to H3 (average of three representative western blots). (A) 
MBD2aTavi is expressed significantly higher in the lung and colon compared to the brain at P7 and 
P42 (*P < 0.05, **P < 0.01, two-way ANOVA with Tukey’s test). (B) MBD1aTavi is expressed 
significantly higher in the brain compared to the lung and colon at P7 and P42 (*P < 0.05, **P < 
0.01, two-way ANOVA with Tukey’s test). (C) MBD2aTavi expression in the brain does not 
significantly change from P7 to P42, but MBD1aTavi is significantly down-regulated in the brain at 
P42 compared to P7. At P42, MBD2aTavi is expressed significantly higher than MBD1aTavi in the 
brain (ns not significant, *P < 0.05, **P < 0.01, two-way ANOVA with Holm-Sidak multiple 
comparison test). All data are presented as mean ±SEM.  
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Figure 3.13. MBD2 expression throughout the adult brain is visualized with β-gal staining. 
(A) Representative β-gal staining of brain regions from P60 wildtype mice shows no staining 
(right). Nissl staining (left) allows for visualization of the tissue structure. (B) Representative β-gal 
staining of brain regions from P60 Mbd2-/- mice shows that MBD2 is expressed throughout all 
brain regions examined, including the olfactory bulb, cortex, striatum, hippocampus, and 
cerebellum (right). Nissl staining (left) allows for visualization of the tissue structure. Scale bars 
correspond to 500µm. 
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Figure 3.14. MBD2 is expressed specifically in epithelial crypt cells of the gastrointestinal 
tract. 
(A) Representative β-gal staining of the small intestine (SI) and colon in P60 wildtype and Mbd2-/- 
mice. There is no staining in wildtype animals, and staining primarily in the epithelial crypt cells of 
both tissues in Mbd2-/- mice. (B) Western blot analysis of spatial expression of MBD2Tavi in the 
small intestine and colon shows that MBD2 is primarily expressed in the epithelial crypt cells of 
both tissues with no detectable expression in villi epithelial cells. Scale bars correspond to 50µm. 
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CHAPTER 4: Discussion and Future Directions 
 
 In summary, I describe in Chapter 2 the results of the first thorough characterization of 
Mbd2 null mice, with emphasis on behavioral phenotypes affected by related MBD proteins. In 
Chapter 3, I present my work on the generation of two novel transgenic mice with biotin-tagged 
endogenous MBD2 or MBD1. I also show the utilization of these mice to explore MBD2 functions 
and spatiotemporal expression in the context of the MBD protein family. Together, this study 
shows several unexpected findings and reveals new insights into MBD2 function in vivo. These 
results elucidate new directions and provide novel genetic tools for further study of MBD2 
functions.  
 
Interpretation of Mbd2 null mice phenotypes 
The majority of MBD proteins have been implicated in brain function in human disease 
and mouse models. Of the MBD proteins, MeCP2, MBD1 and MBD3 are arguably the most 
similar to MBD2 in terms of their DNA binding properties or co-repressor interactions (Baubec et 
al., 2013; Le Guezennec et al., 2006). All of these MBD proteins, and also MBD5, which does not 
bind to methylated DNA but is associated with heterochromatin, have been shown to directly 
affect neuronal functions. All of these MBD protein null mice, with the exception of brain-specific 
Mbd3 null mice which are perinatal lethal, also have notable behavioral deficits in addition to 
underlying cellular phenotypes (Allan et al., 2008; Camarena et al., 2014; Guy et al., 2001; Knock 
et al., 2015; Zhao et al., 2003). It is also well established that DNA methylation and co-repressor 
protein activity, such as histone deacetylases associated with NuRD or the NCoR complexes, are 
essential for brain function (Guan et al., 2009; Guo et al., 2011; McQuown et al., 2011). Due to 
these findings, researchers in the MBD protein field have speculated that MBD2 may have similar 
brain-related functions (Baubec and Schübeler, 2014; Du et al., 2015). Prior to my thesis work, 
the only described behavioral or potentially brain-related phenotype of Mbd2 null (Mbd2-/-) mice 
was impaired pup nurturing and retrieval (Hendrich et al., 2001). This maternal behavior 
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phenotype has been referenced to support a role for MBD2 in brain function and behavior, 
although these phenotypes have complex etiologies (Du et al., 2015; Gammie, 2005). 
With this evidence, it is surprising that we found Mbd2-/- mice are equivalent to wildtype 
and heterozygous littermates in most behavioral tests. Mbd2-/- mice show subtle changes on 
several behavioral tests and other measures, including home-cage hypoactivity, impaired nesting, 
low body weight associated with hypophagia, altered hypothalamic peptide expression, and few 
changes in striatal gene expression. These phenotypes are complex, multigenic, and 
interdependent, and therefore interpretation of their etiologies is challenging. Additionally, these 
phenotypes may be partially dependent on MBD2 functions in peripheral tissues. Specifically, 
MBD2 has been shown to affect gene expression in the gastrointestinal tract and in multiple 
immune cell types (Berger et al., 2007; Cook et al., 2015; Wang et al., 2013).  
Assuming that loss of MBD2 does have effects in peripheral tissues, this further 
complicates the interpretation of these phenotypes because these systems are interrelated. First, 
the gastrointestinal system has an essential role in immune system homeostasis (Macdonald and 
Monteleone, 2005). In addition, body weight is inexorably linked to energy homeostasis (Tou and 
Wade, 2002), which could in turn affect activity levels to produce the hypoactivity and nesting 
deficits we observed in Mbd2-/- mice. The results of the RNA-seq study to identify differentially 
expressed genes (DEGs) in the striatum of Mbd2-/- mice support that immune and metabolic 
phenotypes may be co-occurring to indirectly affect neuronal or behavioral outcomes. Two DEGs 
with a greater than 2-fold change increase in expression are transthyretin (Ttr) and lipocalin2 
(Lcn2), which are both linked to responses to inflammatory, nutritional, or neural injury stress 
(Buxbaum and Reixach, 2009; Lee et al., 2009). Therefore, dysfunction in several systems upon 
constitutive loss of MBD2 could have a synergistic effect on body weight, food intake, and activity 
phenotypes. 
The complexities of these phenotypes could be resolved with additional research. 
Specifically, Mbd2 conditional null mice could be used to isolate tissue- or cell-type specific MBD2 
functions. For example, by crossing a floxed-Mbd2 allele to a mouse expressing Villin-Cre 
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recombinase (Madison et al., 2002) it would be possible delete Mbd2 exclusively from the entire 
intestinal epithelium. Further examination of body weight, food intake and metabolic phenotypes 
between this mouse and the constitutive Mbd2-/- mouse could reveal if low body weight is linked 
directly to intestinal phenotypes. A similar approach could be taken to examine MBD2-related 
phenotypes in lymphoid cell types. For instance, a mouse expressing Cre recombinase 
specifically in FoxP3+ cells (Zhou et al., 2008) could be used to ablate MBD2 expression in Treg 
cells. These cell-type specific approaches may be especially relevant to study MBD2 in immune 
cell types, as MBD2 acts in multiple cell types that influence each other’s maturation and function, 
such as CD4+ T cells and dendritic cells (Aoki et al., 2009; Cook et al., 2015). 
 
Precedents for altered leptin or glucocorticoid receptor signaling in Mbd2 null mice 
It is possible that the phenotypes observed in Mbd2-/- mice do have neuronal origins that 
were not fully elucidated by the experiments described here. First, MBD2 may be affecting the 
regulation of hypothalamic leptin signaling, which in turn could affect food intake, activity levels, 
and body weight. We found that hypothalamic orexigenic and anorexigenic peptides showed 
altered expression in Mbd2 mice, although our findings are not representative of a typical pattern 
of misregulation associated with reduced body weight in other mouse models (Yang et al., 
2014a). Hypothalamic regulation of energy expenditure is regulated primarily by leptin and other 
nutritional signaling (Myers et al., 2008). Transthyretin, which is significantly upregulated in the 
striatum of Mbd2-/- mice, is also affected by leptin levels which supports that these mice may have 
altered leptin signaling (Rendenbach et al., 2013). Previous studies have shown that MeCP2 
affects hypothalamic gene expression and hypothalamic leptin signaling (Ben-Shachar et al., 
2009; Torres-Andrade et al., 2014). Furthermore, there is evidence that hypothalamic leptin 
expression in response to diet-induced obesity is directly regulated through DNA methylation and 
MBD2-related mechanisms (Shen et al., 2014). Therefore, additional experiments are warranted 
to determine if leptin is misregulated in Mbd2-/- mice. It would also be critical to identify if any 
leptin-related phenotypes are hypothalamic, other neuronal, or peripheral in origin. 
 
 104 
 Another possible neuronal origin for Mbd2-/- phenotypes is the misregulation of 
glucocorticoid receptor (GR) signaling. In this study, we hypothesized that altered striatal 
dopamine signaling may underlie many of the phenotypes of Mbd2-/- mice, as highly similar 
phenotypic profiles have been observed in mice with genetic or pharmacological disruption to this 
system (Gammie et al., 2008; Henschen et al., 2013; Jager et al., 2014; Palmiter, 2008). 
However, analysis of biogenic amine levels in the cortex and striatum showed that dopamine and 
its metabolites are equivalent between wildtype and Mbd2-/- mice. An alternative, parallel 
hypothesis is that altered GR signaling in Mbd2-/- mice could contribute to the maternal nurturing 
deficits and possibly other observed phenotypes in Mbd2-/- mice (Hendrich et al., 2001). 
Maternal licking and grooming behaviors drive increased expression of GR in the 
hippocampus, which in turn affects the regulation of stress responses through the hypothalamic–
pituitary–adrenal (HPA) axis (Liu et al., 1997). Maternal behavior is strongly influenced by stress, 
adverse events or other environmental cues and these behaviors can trans-generationally 
influence maternal behavior of female offspring through epigenetic mechanisms (Francis et al., 
1999). The expression of GR in the hippocampus is regulated through methylation of the exon 17 
promoter and recruitment of activating transcription factors, including nerve growth factor-
inducible protein A (NGFI-A). Epigenetic changes at the GR exon 17 promoter in response to 
early environmental cues can persist into adulthood to affect stress responses (Weaver et al., 
2004). 
A recent study showed that MBD2 expression is upregulated in the hippocampus in 
response to maternal licking and grooming, and MBD2 is required for NGFI-A-dependent 
activation of GR expression. Interestingly, the GR exon 17 promoter is generally silenced by DNA 
methylation, but MBD2 and NGFI-A binding activates GR expression. This regulation appears to 
be MBD2-specific, as MeCP2 was not found to interact with the GR exon 17 promoter (Weaver et 
al., 2014). These findings evoke the similar mechanism of FoxP3 regulation in Treg cells, which is 
generally silenced by DNA methylation but becomes demethylated and actively transcribed 
dependent on MBD2 and TET-2 activity (Wang et al., 2013). However, it is unknown if activation 
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of GR is concurrent with demethylation of the exon 17 promoter in a similar MBD2-dependent 
manner. According to this model, a female Mbd2-/- mouse born to a heterozygous mother would 
have an attenuated GR expression response to maternal behavior, leading to long-term 
epigenetic changes at the GR locus. These epigenetic changes could in turn affect this Mbd2-/- 
female mouse’s own maternal nurturing behaviors, as has been observed in female rats whose 
dams were exposed to environmental stress (Francis et al., 1999; Liu et al., 1997; Weaver et al., 
2004). 
Furthermore, if GR signaling is altered in other cell types in Mbd2-/- mice, this 
misregulation could have widespread phenotypic effects. Glucocorticoid signaling is regulated by 
the HPA axis in response to stress and circadian signals through ubiquitously expressed GRs 
(Kadmiel and Cidlowski, 2013). The specificity of glucocorticoid signaling throughout the body is 
achieved by tightly regulated cell-type specific expression levels and post-translational 
modification of different GR isoforms. The GR locus has multiple alternative first exons 
corresponding to different cell-type specific isoforms, each with their own promoter that is 
regulated through DNA methylation and transcription factor binding (Turner et al., 2010). 
It is possible that MBD2 regulates methylation-dependent GR expression in other cell 
types similarly to the hippocampus. GR signaling is systemic and has broad anti-inflammatory, 
anti-proliferative, pro-apoptotic, and anti-angiogenic effects on nearly every organ or system in 
the body. GR signaling has been shown to affect stress responses, inflammatory responses, 
glucose and lipid regulation, and general systemic homeostasis (Kadmiel and Cidlowski, 2013). 
Therefore, it is conceivable that reduced or altered GR signaling in Mbd2-/- mice could underlie 
many of this mouse model’s subtle, non-specific phenotypes, including impaired nurturing, 
hypoactivity, gene expression changes corresponding to stress or inflammation, and low body 
weight. 
 
Potential functional redundancy amongst MBD proteins 
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 Our results showed that loss of MBD2 surprisingly has only subtle effects on behavior 
that may be related to non-neuronal, systemic phenotypes, which suggests that MBD2 may be 
dispensable for brain function. However, our biochemical and spatiotemporal data show that 
MBD2 is expressed at young and adult ages and interacts with the NuRD complex in the brain, 
suggesting an active role. There are several possible models to address this discrepancy. First, it 
is possible that MBD2 does impair neuronal functions, but these changes may be too subtle or in 
too small a population of cells to produce robust changes in behavior. For example, loss of MBD2 
affects maturation and proliferation of olfactory receptor neurons, but Mbd2-/- mice appear to have 
unaffected olfactory ability (Macdonald et al., 2010). Another possibility is that MeCP2, which is 
very highly expressed in the brain throughout development, is able to compensate for loss of 
MBD2 in the brain. Alternatively, it has been proposed that the MBD family proteins may be 
functionally redundant because transcriptional repression is generally maintained in single MBD 
null models (Baubec and Schübeler, 2014).  
Our findings, as they stand alone, support the model of compensation or functional 
redundancy in regard to the role of MBD2 and other MBD proteins specifically in the brain. Our 
data on the spatiotemporal expression of the MBD proteins shows that the brain is unique in 
having relatively high levels of MeCP2, MBD1, MBD2 and MBD3 expression compared to other 
tissues, particularly at younger ages. Therefore it is possible that loss of MBD2 alone in this 
tissue may not cause severe disruptions. MeCP2, which is expressed very highly in the brain and 
is essential for brain function (Guy et al., 2001; Skene et al., 2010), may be the predominant MBD 
protein in this tissue and therefore could be able to compensate for loss of MBD2. Our co-
pulldown results and previous studies show that MBD2 and MeCP2 have certain overlaps in their 
co-repressor protein interactions. Specifically, MBD2 and MeCP2 both interact with HDAC1 and 
SIN3A (Boeke et al., 2000; Nan et al., 1998) in addition to binding to DNA in a mCG-density 
dependent manner (Baubec et al., 2013). However, MeCP2 would not necessarily be able to 
compensate for all MBD2-specific functions with NuRD, as MeCP2 does not interact with all 
members of this complex. 
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However, genetic evidence argues that the MBD proteins are not able to fully 
compensate for each other. Loss of each MBD protein produces distinct phenotypes in mice, 
emphasizing the unique role for each MBD protein (Allan et al., 2008; Guy et al., 2001; Hendrich 
et al., 2001). Loss of both MBD2 and MeCP2 decreases survivability compared to loss of MeCP2 
alone (Martín Caballero et al., 2009). Similarly, loss of MBD2 in mice heterozygous for a Mbd3 
null allele resulted in decreased viability compared to Mbd3 heterozygous mice with wildtype 
MBD2 expression (Hendrich et al., 2001), indicating that MBD2 has other functions for which 
MeCP2 and MBD3 are unable to compensate. There is currently no information on the phenotype 
of mice null for both MBD1 and MBD2, which would help clarify any potential interactions 
between these two MBD proteins. This has been difficult to achieve because the two genes are 
less than 4 Mb apart on the same chromosome. A double null mouse for Mbd2 and Mbd3 would 
also be informative, but may be impossible to achieve because constitutive loss of MBD3 is 
embryonic lethal, while brain-specific ablation of MBD3 is perinatal lethal (Hendrich et al., 2001; 
Knock et al., 2015). 
The argument that the MBD proteins are functionally redundant at the molecular level is 
most applicable to MBD2 and MBD3, which are very closely related both in their protein structure 
and as components of the NuRD complex (Hendrich and Bird, 1998; Le Guezennec et al., 2006). 
However, genetic and biochemical evidence suggests that MBD2 and MBD3 have quite distinct 
properties, which argues against this model. Despite the high level of conservation between 
MBD2 and MBD3, these proteins have entirely different DNA-binding capabilities, which is 
reflected in their distinct genome-wide binding profiles in cell lines (Baubec et al., 2013; Günther 
et al., 2013; Hashimoto et al., 2012a). MBD2 binds specifically to mCG and MBD3 binds with low 
and equivalent affinity to unmodified or modified cytosines (Hashimoto et al., 2012a; Spruijt et al., 
2013). In studies of genome-wide localization, MBD2 is found at methylated CGIs at transcription 
start sites, promoters, and exons, with low enrichment at low mCG-dense regions, such as 
repetitive regions and intergenic sites (Baubec et al., 2013; Günther et al., 2013; Menafra et al., 
2014). MBD2 is also localized at unmethylated, active sites dependent on interactions with NuRD 
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(Baubec et al., 2013). In contrast, MBD3 is found at more unmethylated sites with active 
transcription compared to MBD2 (Günther et al., 2013). One example of MBD2-specific 
transcriptional regulation occurs at the BRCA1-NBR2 locus in HeLa cells where MBD2, but not 
MeCP2 or MBD1, is highly expressed and binds to a constitutively methylated regulatory region 
(Auriol et al., 2005). 
MBD2 and MBD3 also differ in their interactions with the NuRD complex, which could 
result in different tissue-specific functions. MBD3/NuRD may be the primary form of NuRD in the 
brain, as it is abundant in the cerebellum where it affects synaptic connectivity in addition to 
regulating cortical neuronal differentiation (Knock et al., 2015; Yamada et al., 2014). MBD3 also 
interacts with a brain-specific, alternate form of NuRD that incorporates CHD4 in place of CHD5. 
This interaction is specific for MBD3, but it is not clear what the functional significance of the 
CHD4/NuRD complex versus the CHD5/NuRD complex in the brain may be (Potts et al., 2011). 
MBD2 has isoform-specific interactions with NuRD that could have important functional 
consequences, particularly in ESCs (Baubec et al., 2013; Lu et al., 2014). MBD2 also has 
isoform-specific interactions with different protein complexes that may affect NuRD interactions, 
and different genome-wide localization (Baubec et al., 2013; Tan and Nakielny, 2006). However, 
our results did not reveal a notable difference in binding to components of the NuRD complex 
between MBD2 isoforms. This may be due to experimental limitations, which did not permit the 
detection of subtle differences in NuRD interactions, or this mechanism may not occur in the brain 
in vivo. It is not clear if the other binding partners for MBD2 represent specific, NuRD-
independent functions, or if they serve to mediate the interactions between MBD2 and NuRD. 
Either of these scenarios would necessarily indicate that any NuRD-independent MBD2 functions 
are also dispensable for brain function. If MBD2 does have distinct functions independent of 
NuRD, this again raises the question of why loss of MBD2 does not result in a more severe 
phenotype.  
Although our results fit the MBD protein functional redundancy model in the brain, they do 
not support functional redundancy in peripheral tissues. We found that MBD2 is ubiquitously 
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expressed across all tissues examined at adult ages, and most tissues at postnatal day 7. 
MeCP2 is more widely expressed compared to MBD1 and MBD3, but is not co-expressed in all 
tissues with MBD2 expression. MBD3 and MBD1 expression is undetectable in the peripheral 
tissues examined, with the exception of the colon. Therefore, even if some level of functional 
redundancy exists among these proteins, this cannot be occurring in tissues such as the spleen 
or small intestine, where MBD2 is the only MBD protein expressed. 
Our spatiotemporal expression profiling also raises important new questions about the in 
vivo dynamics of the NuRD complex and MBD2 or MBD3.  Biochemical evidence has shown that 
MBD2 and MBD3 are mutually exclusive in the NuRD complex, and that the presence of the MBD 
protein is necessary for NuRD complex formation and function (Le Guezennec et al., 2006; 
Ramírez et al., 2012; Saito and Ishikawa, 2002). It is also apparent that the NuRD complex is 
essential in many tissues and biological processes, including development and tumorigenesis 
(Torchy et al., 2015). We found that MBD2 is associated with NuRD ubiquitously in three 
representative tissues. Our expression data on MBD2 and MBD3 suggest that in adult peripheral 
tissues, NuRD complex functions must depend primarily on MBD2, as MBD2 is highly expressed 
but MBD3 is not detectable. Our expression data for MBD3 indicate that MBD3 may be acting at 
early time points, particularly in the brain. This hypothesis is supported by mouse genetic studies 
that show that a constitutive loss of MBD3 is embryonic lethal, while a brain-specific conditional 
Mbd3 null allele is perinatal lethal with neuronal deficits (Hendrich et al., 2001; Knock et al., 
2015). 
However, if MBD2 is indeed the primary acting MBD protein in adult peripheral tissues, 
this model again poses the question of why Mbd2-/- mice show relatively subtle phenotypes. This 
question can only be answered once the precise in vivo functions of MBD2 and the other MBD 
proteins have been defined. It is clear from genetic, biochemical and expression evidence that 
MBD2 has distinct properties from the other MBD proteins. Therefore, other explanations for the 
absence of a relatively robust Mbd2-/- phenotype besides functional redundancy must be 
considered. 
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Models of MBD2 function and outstanding questions 
An essential goal of the MBD protein field that remains unresolved is defining the precise 
functions of these proteins. Surprisingly, attempts to identify specific methylated loci that show 
direct transcriptional regulation by the MBD proteins have been mostly unsuccessful. Ablation of 
the MBD encoding genes, including Mecp2, Mbd2, or Mbd3, produces many subtle transcriptional 
changes without a clear tendency for aberrant upregulation that would be expected according to 
models of MBD proteins being simple transcriptional repressors (Chahrour et al., 2008; Günther 
et al., 2013). This is especially surprising in the case of MeCP2, because loss or mutation of this 
gene has severe phenotypic consequences (Amir et al., 1999). For MeCP2, this inconsistency 
may be due to the fact that this protein has many other proposed functions, such as chromatin 
organization or stability, that may not necessarily correspond to large, consistent transcriptional 
changes upon loss of MeCP2 (Maunakea et al., 2013; Pohodich and Zoghbi, 2015; Skene et al., 
2010). The picture is less clear for the other MBD proteins, including MBD2. The only described 
functions for MBD2 involve interactions with NuRD or other transcriptional activators and 
repressors, with no proposed major alternative functions (Angrisano et al., 2006; Ramírez et al., 
2012). However, there is increasing evidence that the functions of MBD2 with NuRD are more 
dynamic and complex than originally realized when this protein complex was first identified 
(Baubec et al., 2013; Feng and Zhang, 2001). 
These questions are challenging to resolve because it is experimentally difficult to 
distinguish between functions that are MBD2-specific rather than mediated by the NuRD complex 
as a whole, while the role of MBD3 must also be considered. We anticipate that our 
spatiotemporal expression results will aid in resolving this matter. Studying NuRD complex 
formation and function in a tissue where MBD2 is exclusively expressed may provide insights into 
MBD2-specific functions without the complication of MBD3/NuRD activity. Conversely, it would be 
valuable to compare MBD2/NuRD function to MBD3/NuRD function in the brain of young animals, 
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where these proteins are co-expressed, using conditional loss of MBD2 or MBD3 to examine 
questions of how the NuRD complex forms and functions with either protein.  
One possible model for these interactions in tissues with MBD2 and MBD3 co-expression 
is that MBD3 is essential for NuRD formation and function, while MBD2 represents a more 
transient member of NuRD that is required to fine-tune NuRD function, and thus may be 
expendable. One study determined that most NuRD complexes contain MBD3 rather than MBD2 
(Zhang et al., 1999), but this study was limited to cultured cells, and the dynamics of these 
interactions in vivo have not been fully determined. This scenario is supported by the distinct 
functions of MBD2 and MBD3 in ESCs. MBD3 is absolutely required for embryogenesis, while 
complete ablation of MBD2 does not compromise survivability or fertility (Hendrich et al., 2001). 
However, loss or overexpression of an individual isoform of MBD2 regulates the balance between 
differentiation and proliferation of pluripotent cells (Lu et al., 2014).  
 The different isoforms of MBD2 introduce further complications into models of 
MBD2/NuRD function. With a few important exceptions, most studies of MBD2 do not 
acknowledge or distinguish between the multiple alternatively spliced or translated isoforms. A 
recent study described opposing functions for MBD2a and MBD2c in the differentiation or 
proliferation of ESCs (Lu et al., 2014). Biochemical evidence shows that MBD2a, MBD2b, and 
MBD2c, which is only expressed in the testes and ESCs, have different interactions with NuRD 
and other protein complexes and are recruited to DNA differently (Baubec et al., 2013; Lu et al., 
2014; Tan and Nakielny, 2006). These multiple forms of MBD2 may have distinct roles in other 
cell types that have yet to be fully explored. Similarly to the situation in ESCs, it is possible that 
complete deletion of MBD2 does not have large phenotypic effects, as we have observed. 
Disrupting the balance of MBD2 isoform expression could be more detrimental to NuRD function 
and therefore produce more robust phenotypes similarly to loss of MBD3. 
Finally, another possible explanation for the absence of large transcriptional changes or 
overt phenotypes in Mbd2-/- mice is combinatorial action or redundancy among transcriptional and 
epigenetic regulatory mechanisms. There are multiple interdependent epigenetic mechanisms, 
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such as histone modifications and nucleosome spacing, to safeguard chromatin and 
transcriptional stability. This idea of epigenetic “resilience” means that multiple mechanisms of 
transcriptional regulation can co-exist at a single locus, so that upon loss of one component, the 
transcriptional program or epigenetic state is still maintained (Perissi et al., 2010). This concept is 
especially relevant to induced pluripotent stem cells, which tend to maintain certain epigenetic 
signatures even after reprogramming (Hochedlinger and Jaenisch, 2015). An example of MBD2 
activity in this kind of regulation occurs at the Xist locus. Small amounts of aberrant Xist transcript 
are detectable in the absence of MBD2, but not other MBD proteins. However, other silencing 
mechanisms including HDAC activity were intact in Mbd2 null cells to partially maintain Xist 
repression (Barr et al., 2007).  
This model also allows for more dynamic responses at a single locus, which is supported 
by evidence that DNA methylation and co-repressors such as NuRD may in fact modulate both 
transcriptional activation and repression depending on the epigenomic context (Reynolds et al., 
2013; Suzuki and Bird, 2008). DNA methylation can be associated with active transcription, 
possibly through the binding of activating transcription factors that bind specifically to methylated 
DNA sequences, many with developmental or cell-type specificity (Spruijt et al., 2013). 
Furthermore, the MBD proteins, including MBD2 and NuRD, are localized at many 
transcriptionally active sites (Baubec et al., 2013; Günther et al., 2013). These findings argue for 
a more dynamic picture of methylation-mediated transcriptional regulation than straightforward 
repression by the MBD proteins and their corresponding co-repressor proteins (Reynolds et al., 
2013). 
In conclusion, MBD2 is an integral part of the NuRD complex with many unanswered 
questions regarding its molecular and biological functions. We have shown for the first time that 
loss of MBD2 surprisingly produces few subtle phenotypes, in comparison to mice with loss of 
other MBD proteins (Guy et al., 2001; Hendrich et al., 2001; Zhao et al., 2003). We also 
introduced valuable genetic tools for the study of MBD2 in vivo. We generated two novel 
transgenic mouse lines with endogenous biotin-tagged MBD2 or MBD1, which can be used for 
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numerous experimental applications. We employed these mice to show that MBD2 is expressed 
and associates with the NuRD complex ubiquitously, while the expression of other MBD proteins 
is largely restricted to the brain. The spatiotemporal expression patterns of MBD2 support 
potential functions in several peripheral tissues. These findings also address important questions 
about functional redundancy amongst the MBD proteins as well as the dynamics of the NuRD 
complex with MBD2 and MBD3 in vivo. Future investigations into MBD2 functions may have 
important implications for the study of pluripotency, immunity and cancer. 
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